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ABSTRACT
We have previously identified in the pol gene
of human immunodeficiency virus type 1 (HIV-1) a
new positive transcriptional regulatory element
(nt 4481–4982) containing recognition sites for
nuclear proteins (sites B, C, D and a GC-box)
[C. Van Lint, J. Ghysdael, P. Paras, Jr, A. Burny and
E. Verdin (1994) J. Virol. 68, 2632–2648]. In this
study, we have further physically characterized
each binding site and have shown that the transcrip-
tion factors Oct-1, Oct-2, PU.1, Sp1 and Sp3 interact
in vitro with the pol region. Chromatin immuno-
precipitation assays using HIV-infected cell lines
demonstrated in the context of chromatin that Sp1,
Sp3, Oct-1 and PU.1 are recruited to the HS7 region
in vivo. For each site, we have identified muta-
tions abolishing factor binding to their cognate DNA
sequences without altering the underlying amino
acid sequence of the integrase. By transient trans-
fection assays, we have demonstrated the involve-
ment of the pol binding sites in the transcriptional
enhancing activity of the intragenic region. Our
functional results with multimerized wild-type and
mutated pol binding sites separately (i.e. in the
absence of the other sites) have demonstrated that
the PU.1, Sp1, Sp3 and Oct-1 transcription factors
regulate the transcriptional activity of a heterologous
promoter through their respective HS7 binding sites.
Finally, we have investigated the physiological role
of the HS7 binding sites in HIV-1 replication and
have shown that these sites are important for viral
infectivity.
INTRODUCTION
The expression of human immunodeﬁciency virus type 1
(HIV-1), the etiological agent of AIDS (1–3), is regulated
both at the transcriptional and the post-transcriptional levels
(4). Control of HIV-1 transcription is mediated by cis-acting
elements located in the viral 50-long terminal repeats
(50-LTRs), by the viral trans-regulatory protein Tat and by
cellular transcription factors. In addition to the enhancer
located in the 50-LTR, a 12-O-tetradecanoylphorbol-13-
acetate (TPA)-inducible intragenic enhancer has been identi-
ﬁed in the pol gene of HIV-1 (5). This element is composed
of two functional subdomains encompassing nt 4079–4342
and nt 4781–6026, both exhibiting TPA-inducible enhancing
activity, on the herpes simplex virus (HSV) thymidine kinase
(TK) promoter in HeLa cells (5), but no signiﬁcant activity in
T-lymphoid and monocyte/macrophage cell lines. Never-
theless, analysis of the chromatin organization of integrated
HIV-1 identiﬁed a single major nuclease-hypersensitive site in
the 8 kb region located between the two LTRs (6,7). This
hypersensitive site, centered around nt 4490–4766 [according
to the numbering of the HIV-1 NY5 genome (where nt +1i s
the start of U3 in the 50-LTR)], is located in the part of the pol
gene encoding the integrase protein, precisely between the two
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HeLa cells (7). This constitutive hypersensitive site is present
only in a cell line of monocytic origin (U1) and not in two cell
lines of lymphoid origin (8E5 and ACH2), suggesting a cel-
lular speciﬁcity associated with this intragenic element (6). A
500 bp fragment (nt 4481–4982) encompassing the pol gene
hypersensitive site region (called HS7 region) acts ex vivo as a
cis-acting positive regulatory element. Indeed, when cloned
downstream and in the sense orientation relative to the HIV-1
promoter, the HS7 region reproducibly increases transcription
mediated by the HIV-1 50-LTR (7).
Physical characterization of the HS7 region identiﬁed sev-
eral recognition sites for ubiquitous and cell-type-speciﬁc
nuclear factors, suggesting their involvement in the control
of the transcriptional activity of this region (7). By in vitro
binding studies of the HS7 region, four distinct DNA-binding
motifs for nuclear proteins (called from 50 to 30 site B,GC-box,
site C and site D) were physically deﬁned (Figure 1A). Site B
(nt 4519–4545) speciﬁcally binds four distinct nuclear protein
complexes: an ubiquitous factor (B1), a B-cell speciﬁc factor
(B2), a T-cell speciﬁc factor (B3) and a protein(s) related to
the transcription factor PU.1 (B4) (Figure 1B). The GC-box
(nt 4623–4631) binds puriﬁed Sp1 protein in vitro. Site C
(nt 4681–4701) speciﬁcally binds three nuclear protein
complexes: an ubiquitous factor (C1), a B-cell speciﬁc factor
(C2) and a T-cell speciﬁc factor (C3) (Figure 1C). These
factors have a DNA-binding speciﬁcity similar to that of fac-
tors binding to site B (B1, B2 and B3, respectively). Site D
(nt 4816–4851) speciﬁcally binds an ubiquitously expressed
factor(s) (7). However, the physiological role of these HS7
binding sites in HIV-1 transcription and replication remains
unknown to date.
In this study, we have further characterized physically each
of these four binding sites (sites B, C, D and the GC-box)
located in the HS7 region, examined the functional transcrip-
tional role of each site separately in a heterologous context,
and investigated their biological signiﬁcance in the HIV-1
replication cycle.
MATERIALS AND METHODS
Cell culture
The monocytic cell lines U937 and U1 and the T-lymphoid
cell lines JE6-1 (a clonal line of Jurkat cells), A3.01 (a clonal
derivative of the CEM cell line), the clonal Jurkat JE6-1 cell
lines stably expressing HIV-1 Tat proteins (Tat72 and Tat101)
or the empty vector cassette (8), and ACH2 were maintained
in RPMI 1640-Glutamax I medium (Invitrogen) supplemented
with 10% fetal bovine serum (Myoclone Superplus). The
Figure 1. EMSAanalysisofnuclearfactorsbindingtositeBandtositeC.(A)SummaryofproteinbindingsiteswithinthepolregulatoryregionofHIV-1.(B).The
site B oligonucleotide (50-CAGCATACTTCCTCTTAAAATTAGCAG-30) was labeled, used as probe and incubated with nuclear extracts from human cell lines
of different origins (indicated above the lanes). Retarded DNA–protein complexes (B1, B2, B3 and B4) are indicated by arrows. Adapted with modification from
VanLintetal.(7)withpermission.(C)ThesiteColigonucleotide(50-TAGAATCTATGAATAAAGAAT-30)wasusedasprobeandincubatedwithnuclearextracts
from human cell lines of different origins (indicated above the lanes). Retarded DNA–protein complexes (C1, C2 and C3) are indicated by arrows. Taken with
modification from Van Lint et al. (7) with permission.
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AIDS Research and Reference Reagent Program, National
Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health (NIH). The adherent cell line NIH3T3
(a murine ﬁbroblastic cell line) and 293T cells (human embry-
onic kidney cell line) were cultured in Dulbecco’s modiﬁed
Eagle’s-Glutamax I medium containing 10% calf serum.
The cell line SL2 (a Drosophila cell line) was cultured in
Schneider’s Drosophila medium supplemented with L-glu-
tamine and with 10% fetal bovine serum. All media (Invitro-
gen) also contained 50 U of penicillin/ml and 50 mgo f
streptomycin/ml (Invitrogen). All cells were grown at 37 C
in a 5% CO2 atmosphere, except for SL2 cells which were
grown at 28 C without CO2.
Plasmid constructs
An SmaI–XhoI fragment containing the HIV-1 LAI 50-LTR
(nt 1–789) was puriﬁed from the previously described
pLTR(1-789)-luc construct (9). This fragment was cloned
into the unique EcoICRI–XhoI sites of the reporter vector
pGL3-Basic (Promega). The resulting plasmid was designated
pLTR.
PCR was used to amplify the pol gene fragment (nt 4481–
4982) corresponding to the HS7 region from the infectious
proviral molecular clone pNL4-3 (reagent no. 114, received
from the AIDS Research and Reference Reagent Program,
NIAID, NIH). BamHI sites were introduced in the PCR
primers, and the BamHI-restricted PCR fragment was cloned
in the unique BamHI site of the pLTR, placing the frag-
ment downstream of the 50-LTR-luc transcriptional unit.
The 50 primer oligonucleotide encompassed the coding strand
sequence from nt 4481 to 4505 and contained an added
BamHI restriction site (underlined) at the 50 end (50-TCCC-
CCGGGATCC[nt 4481]GAAGCAGAAGTAATTCCAGCA-
GAG-30). The 30 primer oligonucleotide encompassed the
complementary sequence of the pol gene from nt 4957 to
4982, and contained an added BamHI site (underlined) at
the 50 end (50-TCCCCCGGGATCC[nt 4982]TATTACTAC-
TGCCCCTTCACCTTTCC-30). This plasmid was designated
pLTR-HS7wt. Fragments containing the HS7 region mutated
in the different binding sites (sites B, C, D and the GC-box)
individually or in combination were PCR ampliﬁed from the
pCV11, pCV14, pCV16, pCV19, pCV25, pCV1069 and
pCV1107 plasmids (see below). The 50 and 30 primer oligonu-
cleotides were as described above. The different ampliﬁed
fragments were digested with BamHI and then ligated into
the BamHI site of pLTR to generate pLTR-HS7totmut, pLTR-
HS7mutB/Oct, pLTR-HS7mutB/PU, pLTR-HS7mutC, pLTR-
HS7mutSp, pLTR-HS7mutD and pLTR-HS7mutCmutB/Oct,
respectively.
The pTK reporter plasmid contains the HSV TK minimal
promoter and was described previously (10).
The p(Cwt)3TK was generated by inserting, upstream
of the TK promoter, a double-stranded oligonucleotide
corresponding to three direct repeats of the site C sequence
(50-TAGAATCTATGAATAAAGAAT-30) in the forward
orientation into SmaI-digested pTK-luc. Similarly, the
p(CmutOct)3TK was generated by inserting, upstream of the
TK promoter, a double-stranded oligonucleotide correspond-
ing to three direct repeats of site C mutated in the Oct motif
with the sequence 50-TAGAATCCATGAACAAAGAAT-30
(the mutations are underlined) in the forward orientation
into SmaI-digested pTK.
The p(Bwt)3TK was generated by inserting, upstream of the
TK promoter, a double-stranded oligonucleotide correspond-
ing to three direct repeats of the site B sequence (50-CAG-
CATACTTCCTCTTAAAATTAGCAG-30) in the forward
orientation into SmaI-digested pTK. Similarly, the
p(BmutOct)3TK and p(BmutPU.1)3TK were generated by
inserting, upstream of the TK promoter, a double-stranded
oligonucleotide corresponding to three direct repeats either
of site B mutated in the Oct motif with the sequence
50-CAGCATACTTCCTCTTGAAGTTGGCAG-30, or of site
B mutated in the PU box with the sequence 50-CAGCATAT-
TTTCTCTTAAAATTAGCAG-30 (the mutations are under-
lined) in the forward orientation into SmaI-digested pTK.
The p(Spwt)3TK was generated by inserting, upstream
of the TK promoter, a double-stranded oligonucleotide corre-
sponding to three direct repeats of the Sp site sequence
(50-CCTGTTGGTGGGCGGGGATCAAG-30) in the forward
orientation into SmaI-digested pTK. Similarly, the
p(Spmut)3TK was generated by inserting, upstream of the
TK promoter, a double-stranded oligonucleotide correspond-
ing to three direct repeats of the Sp site mutated in the GC-box
with the sequence 50-CCTGTTGGTGGGCAGGAATCA-
AG-30 (the mutations are underlined) in the forward orienta-
tion into SmaI-digested pTK-luc.
The Oct-1 and Oct-2 expression vectors (pCG-Oct-1 and
pCG-Oct-2) (kindly provided by Dr Winship Herr) contained
the human Oct-1 and Oct-2 cDNAs cloned in the pCG parent
plasmid and were described previously (11). The PU.1 expres-
sion vector pJ6-PU.1 was described previously (12). The Sp1
and Sp3 expression vectors (pPacSp1 and pPacSp3) (kindly
provided by Dr Guntram Suske) contained the human Sp1 and
Sp3 cDNAs cloned in the pPac parent plasmid and were
described previously (13).
Electrophoretic mobility shift assays
Nuclear extracts were prepared by a rapid method described
by Osborn et al. (14). All buffers contained the protease
inhibitors antipain (10 mg/ml), aprotinin (2 mg/ml), chymo-
statin (10 mg/ml), leupeptin (1 mg/ml) and pepstatin (1 mg/ml).
Protein concentrations were determined by the method of
Bradford (15). The DNA sequences of the coding strand of
the double-stranded oligonucleotides used for this study are
listed in Figure 9 or in the ﬁgure legends. Electrophoretic
mobility shift assays (EMSAs) were performed as described
previously (7). Brieﬂy, nuclear extract (15 mg of protein) was
ﬁrst incubated on ice for 10 min in the absence of probe and
speciﬁc competitor DNA in a 16 ml reaction mixture contain-
ing 10 mg of DNase-free BSA (Amersham Biosciences), 2 mg
of poly(dI–dC) (Amersham Biosciences) as non-speciﬁc com-
petitor DNA, 50 mM ZnCl2, 0.25 mM DTT, 20 mM HEPES
(pH 7.3), 60 mM KCl, 1 mM MgCl2, 0.1 mM EDTA and 10%
(v/v) glycerol. 20000 c.p.m. of probe (10–40 fmol) was then
added to the mixture with or without a molar excess of an
unlabeled speciﬁc DNA competitor, and the mixture was incu-
bated for 20 min on ice. Samples were subjected to electro-
phoresis at room temperature on 6% polyacrylamide gels at
150 V for 2–3 h in 1· TGE buffer (25 mM Tris–acetate
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and autoradiographed for 24–48 h at  70 C. For supershift
assays, polyclonal antibodies against Oct-1 (sc-232X), Oct-2
(sc-233X), Sp1 (sc-059X), Sp2 (sc-643X), Sp3 (sc-644X), Sp4
(sc-645X), MEF-2 (sc-10794X) (Santa Cruz Biotechnology),
PU.1 (16), MEF2A, -B or -D (kindly provided by Dr Ron
Prywes) (17), anti-MEF2C (kindly provided by Dr John
Schwarz) (18), or a puriﬁed rabbit immunoglobulin (IgG)
were added to the reaction mixture and incubated for
30 min on ice before the addition of the radiolabeled probe.
For analysis of PU.1 binding, whole-cell extracts of
Spodoptera frugiperda SF9 cells infected with a recombinant
Ac-NPV-PU.1 baculovirus were used as a source for PU.1
protein and extracts from uninfected insect cells were used
as a control. Conditions for EMSAs were as described
previously (19).
Chromatin immunoprecipitation assays
The Chromatin immunoprecipitation (ChIP) assays were per-
formed by using the ChIP assay kit (Upstate Biotechnology)
according to the manufacturer’s recommendations. Formalde-
hyde cross-linking reactions from 5 · 10
6 HIV-infected U1
cells or ACH2 cells were quenched with 125 mM glycine.
Cells were lysed, and chromatin was sonicated to obtain an
average DNA length of 500 bp. Following centrifugation, the
chromatin was diluted 10-fold and precleared with a protein
A–agarose slurry containing salmon sperm DNA and BSA
(Upstate Biotechnology). Precleared chromatin was incubated
overnight at 4 C with no antibody or with 5 mg of either anti-
Oct-1 antibody (sc-232X), anti-Sp1 (sc-59) antibody, anti-Sp3
(sc-644) antibody, anti-PU.1 antibody (sc-352) or normal
rabbit IgG control antibody (Upstate Biotechnology, ref. no.
12-370) as control, followed by immunoprecipitation with
protein A–agarose. Immunoprecipitated complexes were
washed and eluted twice with 200 ml of elution buffer. The
protein–DNA cross links were reversed by heating at 65 C
overnight, and 10% of the recovered DNA was used for PCR
ampliﬁcation (35 cycles) with a primer set amplifying the HS7
region (nt 4497–4769): 50-CCAGCAGAGACAGGGCAA-
GAA-30/50-ACTGCCATTTGTACTGCTGTCTT-30 or with
an unrelated primer set amplifying a pol gene region located
 2 kb upstream of the HS7 region (nt 2326–2573): 50-
TACAGGAGCAGATGATACAG-30/50-CCTGGCTTTAAT-
TTTACTGG-30. PCR products from all reactions were
resolved by agarose gel electrophoresis.
Transient transfection and luciferase reporter assays
NIH3T3 and SL2 cells were transfected using FuGENE -6
(Roche Molecular Biochemicals) according to the manufac-
turer’s protocol. Twenty-four hours before transfection, cells
were seeded at a density of 2 · 10
5 cells/well in 6-well plates.
FuGENE -6 was added directly to serum-free medium 5 min
before addition to the DNA. An aliquot of 100 ml of this
FuGENE -6/serum-free medium mixture was added to the
DNA mixture in microcentrifuge tubes. The mixture was incu-
bated for 15 min at room temperature and, ﬁnally added to
each well of a 6-well plate. Transfected cells were grown in
2 ml of supplemented medium for 40–44 h. Cells were then
lysedandassayedforluciferaseactivity (Promega).Luciferase
activities derived from TK promoters were normalized with
respect to protein concentrations using the Detergent-
Compatible Protein Assay (Bio-Rad).
Jurkat and U937 cells were transfected using jetPEI 
(POLYplus) according to the manufacturer’s protocol. Brieﬂy,
on the day of transfection, cells were harvested at a density of
1 · 10
6/ml, resuspended in fresh complete medium and
seeded at a density of 0.5 · 10
6 cells/well in 12-well plates.
For each well, 1 mg of DNA was diluted into 50 ml of 150 mM
NaCl and 4 ml of jetPEI  were diluted into 50 ml of 150 mM
NaCl. Next, 50 ml of this jetPEI  solution were added to the
50 ml DNA solution. The 100 ml jetPEI /DNA mixture was
then incubated for 15 min at room temperature and, ﬁnally
added dropwise to each well. Transfected cells were grown
in 1.5 ml for 40–44 h, lysed and assayed for luciferase activ-
ity (Promega). All DNA solutions also contained 50 ng of
pRL-TK (used as an internal control for transfection efﬁci-
ency) in which a cDNA encoding Renilla luciferase is under
the control of the HSV TK promoter region (Promega). Fireﬂy
luciferase activities derived from the HIV-1 LTR were
normalized with respect to the Renilla luciferase activities
by using the dual-luciferase reporter assay system (Promega).
Site-directed mutagenesis of the HS7 binding sites
An ApaI/EcoRI fragment containing nt 2011–5743 of the
HIV-1 genome was obtained after digestion with ApaI and
EcoRI of pNL4-3. This fragment was cloned in pBluescript II
SK (Stratagene) digested with ApaI and EcoRI to generate
pCV10. This plasmid was used as a substrate for mutagenesis
of the HS7 binding sites by the transformer site-directed muta-
genesis method (Clontech). The HS7 region was mutated in
all the HS7 sites (site B, Sp site, site C and site D) with the
following ﬁve mutagenic oligonucleotides (mutations are
highlighted in boldface and underlined): CV1 (siteBmutPU.1),
50-CCTGCTAATTTTAAGAGAAAATATGCTGTTTCTTG-
CC-30; CV3 (siteBmutOct), 50-CCTGCCAACTTCAAGAG-
GAAGTATGCTGTTTCTTGCC-30; CV4 (siteBmutOct/
PU.1), 50-CCTGCCAACTTCAAGAGAAAATATGCTGTT-
TCTTGCC-30; CV6 (siteCmutOct), 50-CTTTAATTCTTTGT-
TCATGGATTCTATTACTCCTTGACTTTG-30; CV7 (site-
Spmut), 50-CCTGCTTGATTCCTGCCCACCAAC-30; and
CV14 (siteDmut), 50-GTATGTCTGTTGCTATTATATCGA-
CTATTCTTTCCCCTGC-30.
In addition, three individual mutations of the HS7 site B PU
box, site C or Sp site alone and one double mutation of the
octamer motif in both site B and site C were generated with the
CV1, CV6 or CV7 and CV6/CV3, respectively. The oligonu-
cleotide 50-CTTTTGCTCCCATGGTCTTTCCTG-30, chang-
ing a unique AﬂIII restriction site in pCV10 into a NcoI site
(highlighted in boldface) and the reverse oligonucleotide
50-CTTTTGCTCACATGTTCTTTCCTG-30, changing the
unique NcoI restriction site in a mutated pCV10 into a AﬂIII
site (highlighted in boldface) were successively used for
selection during mutagenesis. The ﬁve mutant resulting
pCV10-derivative plasmids were designated as pCV14
(HS7totmut), pCV11 (HS7mutB/PU), pCV25 (HS7mutC),
pCV19 (HS7mutSp) and pCV16 (HS7mutCmutB/Oct),
respectively. In addition, two other individual mutations
were generated by the QuikChange Site-Directed Mutagenesis
Kit (Stratagene) using the pCV10 construct as a substrate with
the following two pairs of mutagenic oligonucleotide primers
4288 Nucleic Acids Research, 2005, Vol. 33, No. 13(mutations are highlighted in boldface and underlined on
the coding strand primer): CV1141-CV1142 (siteBmutOct),
50-AGCATACTTCCTCTTGAAGTTGGCAGGAAGATGG-
CCA-30 and CV1147-CV1148 (siteDmut), 50-CAGGGGAAA-
GAATAGTCGATATAATAGCAACAGAC-30.
The resulting pCV10-derivative plasmids were designated
as pCV1107 (HS7mutB/Oct) and pCV1069 (HS7mutD),
respectively.
The mutated clones containing the HS7 binding sites
mutated individually or in combination were fully rese-
quenced between ApaI and EcoRI after identiﬁcation (Applied
Biosystems).
Construction of infectious proviruses
containing the HS7 mutations
To eliminate the pUC8 MCS EcoRI site (nt 420) and to keep
only the pol gene EcoRI site (nt 5743), the HIV-1 circularly
permuted single-LTR-containing infectious molecular clone
pEV46 (pHIV, a derivative of pILIC) (20) was partially
digested with EcoRI, dephosphorylated and gel puriﬁed.
The resulting DNA fragment was next ligated to a phospho-
rylated partially double-stranded oligonucleotide. The coding
and non-coding sequences of this oligonucleotide were as
follows: CV20, 50-AATTAGTGGACGTCAC-30 and CV21,
50-AATTGTGACGTCCACT-30, respectively. The resulting
plasmid was designated pCV1. The ApaI/EcoRI mutagenized
fragment from the pCV14 was introduced into the unique
ApaI–EcoRI sites of pCV1 to generate pCV426 (named
pHIV-1*-HS7totmut). As a control, an unmutated ApaI–
EcoRI fragment was puriﬁed from pCV10 and cloned into
the unique ApaI–EcoRI sites of pCV1. We refer to this
construct as pCV422 (named pHIV-1*).
Another set of mutated proviral infectious clones were
also constructed. To that end, the ApaI/EcoRI mutagenized
fragments from pCV14, pCV1107, pCV11, pCV25, pCV19,
pCV1069 and pCV16 were introduced into the unique ApaI–
EcoRI sites of the two LTRs containing proviral clone pNL4.3
to generate pCV1102 (named pHIV-1-HS7totmut), pCV1106
(named pHIV-1-HS7mutB/Oct), pCV1101 (named pHIV-1-
HS7mutB/PU), pCV1105 (pHIV-1-HS7mutC), pCV1104
(named pHIV-1-HS7mutSp), pCV1082 (named pHIV-1-
HS7mutD) and pCV1103 (pHIV-1-HS7mutCmutB/Oct),
respectively. As a control, an unmutated ApaI–EcoRI frag-
ment was puriﬁed from pCV10 and cloned in an identical
manner into the unique ApaI–EcoRI sites of pNL4.3. We
refer to this construct as pHIV-1.
Generation of viral stocks
Wild-type and mutant HIV-1 infectious DNAs were generated
from the single-LTR-containing proviral constructs pCV422
and pCV426, as described above, by BamHI digestion and
self-ligation. These concatemerized proviral DNAs (10 mg)
were transfected into 10
7 Jurkat cells using the DEAE–
dextran procedure. At 24 h post-transfection, the cultures
were cocultivated with 10
7 SupT1 cells to allow rapid and
efﬁcient recovery of progeny virus. HIV-1 wild-type
(HIV-1*) and mutant (HIV-1*-HS7totmut) stocks were pre-
pared at the peak of viral production from supernatants
after ﬁltration through a 0.45 mm pore-size membrane. The
full-length molecular clones pHIV-1, pHIV-1-HS7totmut,
pHIV-1-HS7mutB/Oct, pHIV-1-HS7mutB/PU, pHIV-1-
HS7mutC, pHIV-1-HS7mutSp, pHIV-1-HS7mutD and
pHIV-1-HS7mutCmutB/Oct described above were used to
generate the other stocks of wild-type and mutant viruses
(HIV-1, HIV-1-HS7totmut, HIV-1-HS7mutB/Oct, HIV-
1-HS7mutB/PU, HIV-1-HS7mutC, HIV-1-HS7mutSp, HIV-
1-HS7mutD and HIV-1-HS7mutCmutB/Oct). These DNAs
(3 mg) were transfected into 293T cells by Lipofectamine
2000 (Invitrogen). At 48 h post-transfection, HIV-1 stocks
were prepared from supernatants after ﬁltration through
a 0.45 mm pore-size membrane and stored at [ 80 C. All
viral stocks were quantiﬁed by determining p24 antigen
concentration by an enzyme-linked immunosorbent assay
(ELISA) (Innogenetics).
Viral infections
Infections were performed by incubating 0.5 · 10
6 cells with
50 ng of p24 protein of wild-type or mutant viruses (at 37 C
for 2 h in 500 ml of culture medium). After infection, the cells
were pelleted at 300 g, washed three times with 1 ml of culture
medium, resuspended in 1 ml of standard medium, and grown
under standard conditions. Every 2 or 3 days, aliquots of
200 ml were removed from the infected cultures and replaced
by normal medium. The aliquots were assayed for p24 con-
centration in order to monitor the kinetics of viral replication.
Sequence analysis of HIV-1 genomic RNA
Viral particles from each stock were pelleted by ultracentrifu-
gation (250 ng of p24 at 20000 g for 2 h at 4 C) and digested
with RNase-free DNase I (60 U/ml for 10 min at 4 C; Roche)
in the presence of RNasin (40 U/ml; Promega) to remove con-
taminating DNA. HIV-1 genomic RNA was puriﬁed by using
Trizol Lsreagent(Invitrogen).cDNAsynthesiswasperformed
by the Titan One Tube RT–PCR kit method (Roche Molecular
Biochemicals). cDNAs were ampliﬁed by PCR with a 50
oligonucleotide primer corresponding to nt 4342–4364
(50-CCAGCTGTGATAAATGTCAGCT-30) and a 30 primer
corresponding to nt 4982–4961 (50-TATTACTACTGCCCC-
TTCACC-30). PCR fragments were subcloned into the vector
pCR4 Blunt-TOPO (Zero Blunt TOPO PCR Cloning Kit;
Invitrogen). After identiﬁcation of recombinant clones, three
inserts from each construct were sequenced with the BigDye
terminator sequencing kit (Applied Biosystems). The nucle-
otide sequences of all three clones were identical and con-
ﬁrmed the presence of the original mutations.
RNase protection assays
HIV-1 genomic RNAs were detected by RNase protection
analysis. An HIV-1-speciﬁc
32P-labeled antisense riboprobe
was synthesized in vitro by transcription of pGEM23 (a gift
fromM.Laspia(21)withSP6polymerase.ForHIV-1genomic
RNA analysis, equivalent amounts of viral particles from each
stock (6 mg of p24) were pelleted by ultracentrifugation (at
20000 g for 2 h at 4 C) and viral RNAs were prepared using
Trizol Ls reagent (Invitrogen). The RNase protection assays
were performed with the RPA II kit (Ambion) according to
the manufacturer’s recommendations by using the HIV-1 ribo-
probe as described above. The protected RNA fragments
were analyzed by electrophoresis through 6% urea polyacry-
lamide gels.
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HIV-1 lysates were prepared by ultracentrifugation of each
virus stock and the pellets were resuspended in Laemmli buf-
fer ataconcentration of37.5 ngofp24/ml.Lysates were heated
at 95 C for 5 min, separated by electrophoresis on an 8%
polyacrylamide gel, transferred onto a polyvinylene diﬂuoride
membrane, and probed with a 1:2000 dilution of puriﬁed
human anti-HIV-1 IgG (NIH AIDS Research and Reagent
Program, reagent no. 192 donated by Alfred Prince). A second
antibody, horseradish peroxidase-conjugated goat anti-human
IgG (Pierce) (diluted 1:3300) was used for enhanced chemi-
luminescence detection (Cell Signaling).
RESULTS
Localization of the DNA sequences required for factor
binding to the HS7 sites B and C by substitution
mutant analysis
In order to identify the nuclear factors leading to the formation
of complexes B1/C1, B2/C2 and B3/C3, we performed an
in silico search (using the TESS program) for potential tran-
scription factor binding sites in the HS7 sites B and C. The
numerous potential sites revealed by this in silico analysis
prompted us to perform a systematic substitution-scanning
mutational analysis of sites B and C in order to localize
by in vitro studies the nucleotides important in these sites
for formation of the retarded complexes B1/C1, B2/C2
and B3/C3.
Nine mutant site B oligonucleotides (named m1–m9) were
prepared in which consecutive 3 bp regions of the wild-type
site B were sequentially replaced with a 3 bp C/G-C/G-C/G
sequence (Figure 2A). To examine the effects of these muta-
tions on speciﬁc factor binding to site B, we have systemati-
cally analyzed the ability of the scanning mutants to inhibit
the formation of complexes B1, B2 and B3 in competition
EMSAs.Ifmutationsareintroducedatcriticalpositions, thena
decrease in the ability of the unlabeled mutant oligonucleotide
to compete for factor binding will be detected by the increase
inbandintensityascomparedtothecompetition withthe wild-
type site B. Mutations at non-essential bases are expected to
demonstrate binding competition similar to the wild-type. The
competition assays were performed using site B wild-type as
probe, nuclear extracts from the A3.01 cell line and unlabeled
wild-type and substitution mutant site B double-stranded
oligonucleotides as competitors (Figure 2B). Phosphorimag-
ing analyses were used to quantify the percentage of competi-
tion for formation of complexes B1 and B3 by each of the
unlabeled oligonucleotides. The competition activities of
mutant sites B m1–m9 were expressed relative to the com-
petition activity of the wild-type site B, which was arbitrarily
assigned a value of 100% of competition. Figure 2B shows a
graphicrepresentationofthequantiﬁcationresultsforcomplex
B1. Site B mutants m6, m7 and m8 exhibited the lowest per-
centages of competition (Figure 2B, 44.4, 34.1 and 32.7%,
respectively), indicating that the base pairs which were sub-
stituted in these three double-stranded oligonucleotides, were
the most important for complex B1 formation. Quantiﬁcation
of the bands corresponding to complex B3 indicated the
importance of the same base pair (data not shown). Similar
results were observed for complexes B1 and B2 when
identical experiments were conducted with Raji nuclear
extracts (Figure 2C). These results demonstrate that
nucleotides between 4534 and 4542 in site B are critical for
formation of all three complexes B1, B2 and B3, suggesting
the presence of overlapping binding sites in site B or com-
petition among factors for the same site.
We next prepared seven scanning mutants of site C (named
m1–m7),which sequentially replace 3bp ata time ofthe entire
site C sequence with a CCC sequence (Figure 2D). We tested
the ability of this set of substitution mutants to inhibit forma-
tion of complexes C1, C2 and C3 in competition EMSAs
using wild-type site C as probe, A3.01 nuclear extracts and
the unlabeled wild-type and mutant double-stranded oligonu-
cleotides as competitors (Figure 2E). Phosphorimaging
analyses were used to quantify the percentage of competition
for the formation of complexes C1 and C3 by each of the
unlabeled oligonucleotides. The competition activities of mut-
ant sites C m1–m7 were expressed relative to the competition
activity of the wild-type site C, which was arbitrarily assigned
to a value of 100% of competition. Figure 2E shows a graphic
representation of the quantiﬁcation results for complex C1.
Site C mutants m3, m4 and m5 exhibited signiﬁcantly reduced
competition activities (Figure 2B, 55.4, 20.3 and 25.2%,
respectively), indicating that the base pairs which were sub-
stituted in these three oligonucleotides were the most impor-
tant for complex C1 formation. Quantiﬁcation of the bands
corresponding to complex C3 indicated the importance of the
same base pair (data not shown). Similar results were observed
for complexes C1 and C2 when identical experiments were
conducted with Raji nuclear extracts (Figure 2F). These results
demonstrate that nucleotides between 4687 and 4695 in site C
are critical for the formation of all three complexes C1, C2 and
C3, suggesting the presence of overlapping binding sites in
site C or competition among factors for the same site.
In addition, we conﬁrmed these results by complementary
experiments in which a labeled probe containing site B was
used and complex formation was competed by unlabeled
oligonucleotides containing wild-type and mutant sites C,
as well as by reverse experiments in which a labeled probe
containing site C was used and complex formation was com-
peted by unlabeled oligonucleotides containing wild-type
and mutant sites B (data not shown), conﬁrming that factors
binding to site C have a DNA-binding speciﬁcity similar to
that of factors binding to site B, except for PU.1. These data
are in agreement with our previous work (7).
In conclusion, our results indicate that the DNA sequences
identiﬁed here as critical for factors binding to sites B and C
are located between nt 4534 and 4542 and between nt 4687
and 4695, respectively.
The transcription factors Oct-1 and Oct-2
bind to sites B and C
Based on the above systematic mutational analysis, we per-
formed a new computer search for potential transcription fac-
tor binding sites, which was focused on the critical nucleotide
sequences of sites B and C. This search revealed the presence
of a putative octamer regulatory sequence both in site B and in
site C (Figure 3A, nt 4532–4539 in site B and nt 4689–4696 in
site C). These two putative octamer sequences presented three
4290 Nucleic Acids Research, 2005, Vol. 33, No. 13mismatches with respect to the Oct consensus. Oct-1 and
Oct-2 along with Pit-1 and Unc-86 are founding members
of the POU family of transcription factors. These members
show homology in the domain responsible for speciﬁc
DNA-binding, the so-called POU domain. While Oct-1 is
ubiquitous, Oct-2 is predominantly expressed in B-cells, as
well as in activated T-cells and in nervous system. However,
B-cells appear to contain the highest amounts of Oct-2
(22,23).
To determine whether transcription factors binding to sites
B and C are related to Oct proteins, unlabeled double-stranded
oligonucleotides were prepared and used as competitors in
EMSAs. Site C probe was incubated with nuclear extracts
from Jurkat cells in the absence or in the presence of different
competitor double-stranded oligonucleotides: the unlabeled
homologous oligonucleotide, anunlabeledheterologousoligo-
nucleotide corresponding to site D and an unlabeled oligonu-
cleotide corresponding to the octamer consensus sequence
(Figure 3B). In the absence of competitor, two retarded
complexes were detected: the ubiquitous complex C1 and
the T-cell speciﬁc complex C3 (Figure 3B, lane 1). Formation
of complex C1 was inhibited by a molar excess of unlabeled
homologous oligonucleotide (Figure 3B, lanes 2–7), by the
Oct consensus oligonucleotide (Figure 3B, lanes 14–19), but
Figure 2. Identification of the DNA sequences required for factor binding to the HS7 sites B and C. (A) Nucleotide sequences of the wild-type and mutant site B
oligonucleotides are shown with underlined bases indicating the base pairs required for the formation of complexes B1, B2 and B3. For the mutant site B
oligonucleotides, only the bases that are changed compared with the wild-type sequence are indicated. The wild-type site B oligonucleotide was 50 end labeled
andusedasprobeinEMSAcompetitionexperimentswithnuclearextractsfromA3.01cells(B)orRajicells(C)andwild-typeandsubstitutionmutantsiteBdouble-
stranded oligonucleotides as competitors. Binding assays were performed in the absence of competitor or in the presence of a 100-fold molar excess of either the
homologous site B oligonucleotide or one of the nine mutated sites B (m1–m9). The competitor used is indicated at the top of each lane. The figure shows only the
specific retarded bands of interest. The complexes B1 and B3 (B) or B1 and B2 (C) are indicated by arrows. Quantification of EMSAs was performed with an
InstantImager (Packard) and is shown for the B1 complex in both (B and C). The histograms indicate the competition activities of site B m1–m9 mutants expressed
relative to the competition activity of the wild-type site B (100%). (D) Nucleotide sequences of the wild-type and mutant site C oligonucleotides are shown with
underlined bases indicating the base pairs required for the formation of complexes C1, C2 and C3. The 3 bp region different from the wild-type site C sequence is
indicatedin the seven mutantsite C oligonucleotides (m1–m7).The wild-typesite C used as probe was incubatedwith nuclear extracts from A3.01cells (E) or Raji
cells(F)andwild-typeandsubstitutionmutantsiteCdouble-strandedoligonucleotidesascompetitors.Bindingassayswereperformedintheabsenceofcompetitor
or in the presence of a 100-fold molar excess of either the homologous site C oligonucleotide or one of the seven mutated sites C (m1–m7). The competitor used is
indicatedatthetopofeachlane.Thefigureshowsonlythespecificretardedbandsofinterest.ThecomplexesC1andC3(E)orC1andC2(F)areindicatedbyarrows.
QuantificationofEMSAswasperformedwithanInstantImager(Packard)andisshownfortheC1complexinboth(EandF).Thehistogramsindicatethecompetition
activities of site C m1–m7 mutants expressed relative to the competition activity of the wild-type site C (100%).
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ing site D (Figure 3B, lanes 8–13). Complex C3 was also out-
competed by the homologous site Coligonucleotide and by the
Oct consensus oligonucleotide(althoughtoa lesser extent than
complex C1) but not by the site D oligonucleotide. Similar
competition experiments using site C as probe and nuclear
extracts from Raji cells conﬁrmed the above results for
complex C1 and indicated that complex C2 was inhibited
by an excess of unlabeled homologous oligonucleotide and
by the Oct consensus, but not by the unrelated site D oligo-
nucleotide (data not shown). We conclude from these experi-
ments that the ubiquitous complex C1, the B-cell-speciﬁc
complex C2 and the T-cell-speciﬁc complex C3 could contain
a member(s) of the Oct proteins. Similar competition experi-
ments performed with site B as probe supported the notion that
formation of complexes B1, B2 and to a lesser extent B3 also
resulted from binding of proteins belonging to the Oct family
(data not shown).
To identify directly the factors present in the speciﬁc com-
plexes B1/C1, B2/C2 and B3/C3, we performed supershift
assays using antibodies directed against two individual mem-
bers of the Oct family of transcription factors: the ubiquitously
expressed Oct-1 protein and the lymphoid-speciﬁc Oct-2
protein. Labeled site C oligonucleotide probe was incubated
with nuclear extracts from Jurkat or Raji cells in the presence
of either an anti-Oct-1 antibody or an anti-Oct-2 antibody or
puriﬁed rabbit IgG as control (Figure 3C). With Jurkat nuclear
extracts, we observed, in the presence of the IgG control, the
formation of the ubiquitous complex C1 and of the T-cell-
speciﬁc complex C3 (Figure 3C, lane 1). Addition of the
anti-Oct-1 antibody resulted in the complete disappearance
of complex C1 (Figure 3C, lane 3), whereas the addition of
the anti-Oct-2 antibody did not modify the migration proﬁle of
complexes C1 and C3 (Figure 3C, lane 5). With Raji nuclear
extracts, we observed, in the presence of the IgG control, the
formation of the ubiquitous complex C1 and the B-cell-
speciﬁc complex C2 (Figure 3B, lane 2). The anti-Oct-1 anti-
body completely eliminated complex C1 (Figure 3C, lane 4)
and complex C2 was eliminated by the anti-Oct-2 antibody
(Figure 3C, lane 6). Similar results were obtained for com-
plexes B1, B2 and B3 when identical experiments were con-
ducted with site B as probe (data not shown).
In order to identify the protein(s) present in complexes
B3/C3, we ﬁrst tested, by supershift experiments, a series of
protein candidates for potential transcription factor binding
sites revealed by our in silico analysis: among others, the
Figure 3. Oct-1andOct-2specificallyinteractwithsiteC.(A)Thenucleotidesequenceofthewild-typesitesBandColigonucleotidesarealignedwiththeoctamer
consensusmotif.TheasterisksindicatethemismatchesofthepotentialsiteBandsiteCoctamermotifswithrespecttotheoctamerconsensus.ThebracketsinsiteB
and site C show the 9 bp (identified in Figure 2) as critical for the formation of complexes B1, B2 and B3 and C1, C2, and C3, respectively. (B) The site C
oligonucleotideprobewasincubatedwithnuclearextracts fromJurkat cells.Bindingassayswereperformedin the absenceofcompetitor(lane1)orin the presence
of increasing concentrations (5-, 10-, 25-, 50-, 100- or 200-fold molar excess) of the homologous site C oligonucleotide (lanes 2–7), of the heterologous HS7 site D
oligonucleotide (lanes 8–13) or of the Oct consensus oligonucleotide (lanes 14–19). The sequence of the coding strand of the Oct consensus oligonucleotide was as
follows:50-TGTCGAATGCAAATCACTAGAA-30.ThesequenceofthecodingstrandoftheHS7siteDoligonucleotideisshowninFigure7.Thefigureshowsonly
the specific retarded bands of interest. The complexes C1 and C3 are indicated by arrows. (C) Antibodies directed against Oct-1 (lanes 3 and 4) and Oct-2 (lanes 5
and 6)orpurifiedrabbitIgGasnegativecontrol(lanes1and2) wereincubatedwith15mg ofnuclearextractsfromJurkat (lanes1,3 and5)orRaji(lanes2, 4and6)
cellsbeforetheadditionofthesiteColigonucleotideprobe.Thefigureshowsonlythespecificretardedbandsofinterest.TheretardedDNA–proteincomplexesC1,
C2 and C3 are indicated by arrows.
4292 Nucleic Acids Research, 2005, Vol. 33, No. 13members of the MEF-2 transcription factor family. However,
the latter assays did not provide any clue about the identity
of the complexes B3/C3. Of note, the validity and/or the
speciﬁcity of the different a-MEF-2 (a-MEF-2A, -2B, -2C
and -2D) antibodies were established in separate experiments
(data not shown). We also tried to purify complexes B3/C3
by afﬁnity chromatography. However, despite many attempts,
we did not succeed in the identiﬁcation of these B3/C3 com-
plexes. Additional puriﬁcation and microsequencing studies
are currently underway in our laboratory to identify the nature
of the protein(s) present in complexes B3/C3.
From these data, we conclude that the ubiquitous complexes
B1/C1 contain the Oct-1 transcription factor and that the B-
cell-speciﬁc complexes B2/C2 contain the Oct-2 transcription
factor. The transcription factor(s) present in the T-cell-speciﬁc
complexes B3/C3 still remains (remain) to be identiﬁed.
The transcription factor PU.1 specifically interacts with
site B of the HS7 region to form complex B4
ComplexB4 was previouslydemonstrated by ourlaboratory to
contain a protein related to the transcription factor PU.1 (7).
Indeed, our laboratory has previously reported that a SV40
PU.1 consensus oligonucleotide inhibits speciﬁcally the
formation of complex B4, whereas no competition of binding
in complexes B1 and B2 was observed. We have also previ-
ously shown that the PU.1 protein, derived from lysates of
Cos-1 cells transfected with a PU.1 expression vector, binds to
site B in a PU box-dependent manner. Nevertheless, because
proteins that bind DNA by means of an Ets domain share DNA
recognition properties, we could not rule out the possibility
that other Ets family members also bind to the PU box present
in the HS7 site B (Figure 4A).
To determine directly the presence of PU.1 in complex B4,
we performed supershift assays. Preimmune serum or anti-
serum speciﬁc for PU.1 was incubated with nuclear extracts
from U937 cells before the addition of the labeled probe cor-
responding to site B (Figure 4B). We observed that the addi-
tion of the anti-PU.1 antibody interfered with the formation of
complex B4, leading to its disappearance (Figure 4B, lane 2).
In contrast, the preimmune serum did not affect complex B4
formation (Figure 4B, lane 1), indicating the speciﬁcity of
the protein–antibody interaction. These results indicated that
the B4 complex contained PU.1. In addition, we also demon-
strated that PU.1 protein produced in baculovirus bound to
site B and induced the formation of a complex comigrating
with complex B4 (Figure 4B, compare lanes 3 and 4).
In conclusion, the macrophage- and B-cell-speciﬁc tran-
scription factor PU.1 speciﬁcally interacts with site B in the
HIV-1 HS7 region. Moreover, the comigration of complex B4
with puriﬁed PU.1 protein and the complete disappearance of
complex B4 when using the anti-PU.1 antiserum suggest that
this complex does not contain other Ets proteins.
The transcription factors Sp1 and Sp3 specifically
interact with the GC-box located in the
HIV-1 HS7 region
We have previously identiﬁed a GC-box with close homology
to the Sp1 consensus sequence at position nt 4623–4631 in
the HS7 region and we have shown, by in vitro DNase I
footprinting analysis, that this site binds afﬁnity-puriﬁed
human Sp1 protein (7). In order to further assess the presence
of Sp1 and/or other Sp family members on this GC-box, we
designed a double-stranded oligonucleotide, and designed
site Sp wt (nt 4616–4638) encompassing the potential Sp
site (Figure 5A). This oligonucleotide was radiolabeled and
tested in EMSAs for DNA–protein interactions with nuclear
extracts from Jurkat cells (Figure 5B). Two retarded protein–
DNA complexes were observed. Similar results were obtained
with nuclear extracts from the U937, Raji and A30.1 cell lines
(data not shown). To evaluate the sequence speciﬁcity of
the binding to the Sp wt probe, we performed competition
EMSAs using increasing concentrations of different unlabeled
double-stranded competitor oligonucleotides (Figure 5B). The
speciﬁcity of the protein binding was demonstrated because
their formation was inhibited by competition with molar
excesses of the unlabeled homologous Sp wt oligonucleotide
(Figure 5B, lanes 2–5), but not by the same molar excesses
of a heterologous oligonucleotide corresponding to site B
(Figure 5B, lanes 14–17). A Sp1 consensus oligonucleotide
(named Sp1 cons) inhibited the formation of the retarded
complexes even at lower concentrations than the homologous
Figure 4. The complex B4 of the HS7 site B contains PU.1. (A) Nucleotide
sequence of the wild-type site B oligonucleotide with the PU box indicated by
an arrow on the non-coding strand. The core sequence 50-GGAA-30 of the PU
box is indicated by a thicker bar. (B) Nuclear extracts from U937 cells (15 mg)
were incubated in the absence of antibody (lane 3) or in the presence of a
PU.1-specific antiserum (lane 2) or the preimmune rabbit serum as a negative
control (lane 1) before the addition of the site B oligonucleotide probe. The
same probe was also incubated with whole-cell extracts from SF9 cells
infected with an Ac-NVP-PU.1 recombinant baculovirus (PU.1 baculovirus,
lane4).TheDNA–proteincomplexesB1andB4,thePU.1complexandthefree
probe (FP) are indicated by arrows.
Nucleic Acids Research, 2005, Vol. 33, No. 13 4293oligonucleotide (Figure 5B, lanes 6–9). In contrast, these com-
plexes were not competed by a mutated version of the Sp1
consensus oligonucleotide (named Sp1 cons mut) containing
a GG to TT substitution, thereby demonstrating the speciﬁcity
of the retarded complexes to the HS7 Sp motif (Figure 5B,
lanes 10–13). These results support the hypothesis that both
complexes contain Sp family members.
To identify directly the Sp family members within the two
retarded complexes observed with the HS7 Sp wt probe, we
performed supershift assays using speciﬁc antibodies directed
against individual members of the Sp family of transcription
factors (Figure 5C). The HS7 Sp wt probe was incubated with
nuclear extracts from Jurkat cells and polyclonal antibodies
directed against Sp1, Sp2, Sp3 or Sp4 were added to the
binding reaction mixture (Figure 5C and data not shown).
The a-Sp1 antibody selectively supershifted the major slower
migrating complex (Figure 5C, lane 3) and the a-Sp3 antibody
resulted in the appearance of a supershifted complex and the
corresponding disappearance of the faster migrating complex
(Figure 5C, lane 4). We conﬁrmed these results when both
anti-Sp1 and anti-Sp3 antibodies were included in the same
binding reaction (Figure 5C, lane 5). Similar relative mobili-
ties of Sp1 and Sp3 EMSA complexes were reported in pre-
vious studies (24–27). In contrast, the binding pattern was not
affected by the addition of the antibodies directed against the
otherSpproteins(Sp2andSp4)(datanotshown),showingthat
the two complexes did not seem to involve these other pro-
teins. Moreover, the binding pattern was not affected by the
addition of an unrelated antibody against MEF-2, used as a
negative control (Figure 5C, lane 2).
Overall, these results demonstrate that Sp1 and Sp3 tran-
scription factors interact with the GC-box (renamed Sp site
hereafter in the manuscript) located in the intragenic HS7
region of HIV-1.
Figure 5. Sp proteins bind to the GC-box located in the HS7 region. (A) The nucleotide sequence of the wild-type Sp site oligonucleotide is aligned with the Sp1
consensussequence.TheGC-boxpresentintheSpsiteisindicatedbyanarrowandtherecognitioncoresequence50-GG-30 isindicatedbyathickerbar.(B)TheHS7
Sp wtsite oligonucleotideprobe wasincubatedwith15 mg ofnuclear extractsfrom Jurkat cells in theabsenceof competitor (lane1) orin the presenceofincreasing
concentrations (25-, 50-, 100- or 200-fold molar excess) of the homologous HS7 Sp site wt oligonucleotide (lanes 2–5), of the Sp1 consensus oligonucleotide
(lanes 6–9), of a mutatedSp1 consensusoligonucleotide(lanes 10–13)or ofthe heterologous HS7 site B oligonucleotide (lanes 14–17).The sequence ofthe coding
strandoftheSp1consensusoligonucleotideandthesequenceofthemutatedSp1consensusoligonucleotidewereasfollows:50-ATTCGATCGGGGCGGGGCGAG-
30 and 50-ATTCGATCGGTTCGGGGCGAGC-30, respectively. The figure shows only the specific retarded bands of interest. The two retarded DNA–protein
complexesareindicatedbyarrows.(C)NuclearextractsfromJurkatcells(15mg)wereincubatedintheabsenceofantibodyorinthepresenceofantibodiesdirected
againstMEF-2,Sp1and/orSp3(asindicatedatthetopofeachlane)beforetheadditionoftheHS7Spwtsiteoligonucleotideprobe.Thefigureshowsonlythespecific
retarded bands. The retarded DNA–protein complexes and the supershifted complexes are indicated by arrows.
4294 Nucleic Acids Research, 2005, Vol. 33, No. 13Transcription factor(s) binding to site D seems (seem)
to contain a zinc finger DNA-binding domain
Our laboratory has previously reported that an ubiquitously
expressed factor(s) interacts (interact) speciﬁcally with
site D (7). This site is well conserved among many HIV-1
isolates, but computer analysis has revealed no relevant homo-
logy between this binding site and the recognition sequences
for known transcription factors (7). Methylation interference
analysis of site D has identiﬁed the guanine residues that are
important for binding: methylation of two guanine residues
at positions 4830 and 4833 on the coding strand and of one
guanine residue at position 4835 on the non-coding strand has
been shown to strongly interfere with binding to site D (7).
In this study, we further characterized site D by EMSAs to
identify the protein(s) present in complex D. Since many tran-
scriptionfactors are zinc ﬁngerproteins, the probe correspond-
ing to site D was incubated with nuclear extracts from Jurkat
cells in the absence or in the presence of increasing concen-
trations of a chelator of zinc, the 1,10-phenanthroline. Incuba-
tion of this site D probe resulted in one major ubiquitous
retarded complex (labeled D) (Figure 6, lane 1) as previously
reported by our laboratory (7). We observed that complex D
disappeared in the presence of phenanthroline (Figure 6,
lanes 2–5). The presence of increasing concentrations of
ZnCl2 caused the restoration of complex D (Figure 6, lanes
6–9), whereas the presence of increasing concentrations of
another ion (MgCl2) did not allow the reappearance of com-
plex D (Figure 6, lanes 10–13).
We conclude that the binding of the ubiquitously expressed
protein(s) to site D is Zn
2+-dependent. This observation sug-
gests that this (these) protein(s) could contain zinc ﬁnger
domain(s). However, despite many puriﬁcation and protein
sequencing attempts, we did not succeed to identify this
(these) protein(s).
Tat expression does not affect the binding of the nuclear
factors to the HS7 binding sites
To determine whether Tat can inﬂuence the binding of factors
to the HS7 binding sites, we performed EMSAs, using nuclear
extracts prepared from clonal Jurkat cell lines that stably
expressed either the one-exon form of Tat [72 amino acids
(Tat72)] (Figure 7, lane 2) or the two-exon form of Tat [101
amino acids (Tat101)] (Figure 7, lane 3) (8). Nuclear extracts
from a clone transfected with the empty expression cassette
vector were used as controls (Figure 7, lane 1). Both forms of
Tat were used because Tat101 is expressed both early and late
in the virus life cycle, while Tat72 is expressed solely in the
late phase (28). Probes corresponding to HS7 site B, Sp site,
site C and site D were incubated with these nuclear extracts.
No difference in binding activity between the Tat72 and
the Tat101 clones and the control clone was noted when the
four probes were used (Figure 7, compare lanes 2 and 3 with
lane 1).
We conclude from these in vitro experiments that Tat has no
effect on nuclear factor binding to the HS7 intragenic region.
Sp1, Sp3, Oct-1 and PU.1 are recruited to the HS7
regulatory region in vivo
To demonstrate in vivo in the context of chromatin the rele-
vance of our in vitro binding studies, we performed chromatin
ChIP assays using both the lymphoid HIV-infected ACH2 cell
line and the monocytic HIV-infected U1 cell line. Formalde-
hyde cross-linked chromatin from these cell lines was used for
immunoprecipitation with antibodies directed against Sp1,
Sp3, Oct-1 or PU.1 or a puriﬁed rabbit IgG as negative control.
Following reverse of the cross-link, the puriﬁed DNA was
subjected to PCR analysis using a set of primers ﬂanking
the HS7 region (Figure 8). In ACH2 cells, Oct-1, Sp1 and
Sp3 binding to the HS7 region was detected (Figure 8A,
lanes 1, 2 and 3, respectively), whereas, as expected, immuno-
precipitations of the cross-linked chromatin with the anti-
PU.1 antibody or with the puriﬁed rabbit IgG gave no signal
(Figure 8A, lanes 4 or 5, respectively). In U1 cells, analysis of
Figure 6. Binding of nuclear factors to the HS7 site D is Zn
2+-dependent. The
siteDoligonucleotideprobewasincubatedwith15mgofnuclearextractsfrom
Jurkat cells in the absence (lane 1) or in the presence of increasing concentra-
tions (0.5, 1, 1.5 and 2 mM) of 1,10-phenanthroline (lanes 2–13). Increasing
amountsofZnCl2(0.4,0.8,1and1.2mM)orofMgCl2(0.4,0.8,1and1.2mM)
were added to the binding reactions (lanes 6–9 or lanes 10–13, respectively).
The figure shows only the specific retarded bands of interest. The complex D
is indicated by an arrow.
Figure 7. Analysis of Tat effect on factors binding to the HS7 sites. Probes
corresponding to the HS7 site B, Sp site, site C or site D were incubated with
15 mg of nuclear extracts from clonal Jurkat cell lines expressing either Tat72
(lane 2) or Tat101 (lane 3) or the empty vector cassette as control (lane 1). The
figure shows only the specific retarded bands of interest. The retarded com-
plexes corresponding to Oct-1, C3, Sp1, Sp3 and D are indicated by arrows.
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signiﬁcant enrichment of the HS7 region when immuno-
precipitation was carried out with the anti-Oct-1, anti-Sp1,
anti-Sp3 or anti-PU.1 antibodies (Figure 8B, lanes 1, 2, 3 or 4,
respectively). In contrast, no such enrichment was observed
following immunoprecipitation of the cross-linked chromatin
with the puriﬁed rabbit IgG (Figure 8B, lane 5). As a control,
we used another set of primers ﬂanking a region of the pol
gene located 2 kb upstream of the HS7 region that has not been
reported so far as binding any of these transcription factors.
Immunoprecipitations with all the antibodies did not enrich
eluates with DNA from this control region in both ACH2 and
U1 cell chromatin, demonstrating the speciﬁcity of the HS7
interactions (data not shown).
These data, thus, demonstrate the occupancy in vivo of the
HS7 region by Oct-1, Sp1 and Sp3 in both ACH2 and U1 cell
lines as well as, consistently, the binding of PU.1 to the HS7
only in the U1 cells.
Identification of point mutations abolishing factor
binding to the DNA motifs in the HIV-1 HS7 region
To further characterize physically the DNA motifs located in
the HS7 region of the pol gene, we studied by using EMSA
the effect of selected mutations on binding afﬁnity. Point
mutations were designed to abolish binding of factors to
their respective sites without modifying the underlying amino
acid sequence of the integrase.
(i) Site B: We demonstrated that Oct-1, Oct-2 and PU.1
bound to site B. To abolish binding of Oct-1 and Oct-2,
three adenine residues at positions 4535, 4538 and 4541
were substituted with guanine residues (Figure 9A). The
oligonucleotidecorresponding tothismutationwas desig-
natedsiteBmutOct.ToabolishPU.1bindingtositeB,two
cytosine residues at positions 4526 and 4529 were substi-
tuted with thymine residues in the site B PU box
(Figure 9A). The oligonucleotide corresponding to this
mutation was designated site B mutPU.1. The effect of
these selected mutations was analyzed on binding affinity
by using EMSAs. The wild-type and the two mutated
siteBoligonucleotideswereusedasprobesandwereincu-
bated with nuclear extracts from U937 (Figure 9A), Raji
andJurkat(datanotshown)cells.Figure9Ademonstrated
thelackofOct-1bindingtothesiteBmutOctoligonucleo-
tideprobe(lane2)andthelackofPU.1bindingtothesiteB
mutPU.1 oligonucleotide probe (lane 3). Similar experi-
mentsusingRajinuclearextractsshowedthelackofOct-2
binding to the site B mutOct oligonucleotide and con-
firmed the lack of PU.1 binding to site B mutPU.1 oligo-
nucleotide probe (data not shown). Similar EMSAs using
JurkatnuclearextractsconfirmedthelackofOct-1binding
andshowedthelackofT-cell-specificbindingtothesiteB
mutOct oligonucleotide probe (data not shown). Taken
together, our results identify an octamer motif and a PU
boxintheHS7siteB.Theoctamermotifspecificallybinds
the octamer proteins Oct-1 and Oct-2 in vitro.The PU box
specifically binds the Ets protein PU.1. We report a 3 bp
mutation, referred to as site B mutOct, that abrogates the
binding of Oct-1 and Oct-2 and binding of the T-cell-
specific factor to site Band a 2bp point mutation,referred
toassiteBmutPU.1,thatabrogatesPU.1bindingtositeB.
(ii) Sp site: We showed that Sp1 and Sp3 bound to the HS7
GC-box. Two guanine residues at positions 4629 and
4632 were substituted with two adenine residues in this
motif (Figure 9B). The wild-type and the mutated oligo-
nucleotide(referredtoassiteSpwtandsiteSpmut,respec-
tively) were used as probes and incubated with nuclear
extracts from U937 cells. Figure 9B showed the lack of
Sp1 and Sp3 binding to the site Sp mut oligonucleotide
probe, thereby demonstrating that the selected 2 bp muta-
tion abolished Sp binding to the HS7 Sp site.
(iii) Site C: We demonstrated that Oct-1, Oct-2 and a T-cell
factor(s) bound to the HS7 site C. To abolish factor bind-
ingtothissite,twothymineresiduesatpositions4688and
4694 were substituted with cytosine residues in the octa-
mer sequence of site C (Figure 9C). The effect of this 2 bp
mutation on binding affinity was analyzed by EMSAs.
The wild-type and the mutated oligonucleotides (referred
to as site C wt and site C mutOct, respectively) were used
as probes and incubated with Raji (Figure 9C) or Jurkat
nuclear extracts (data not shown). Figure 9C showed the
lack of Oct-1 and Oct-2 binding to the site C mutOct oli-
gonucleotide probe. Similar EMSAs using Jurkat nuclear
extracts confirmed the lack of Oct-1 binding and showed
the lack of T-cell-specific binding to the same mutated
probe (data not shown). These results demonstrated
thatthe selectedpoint mutations introduced insiteCabol-
ished both the binding of Oct-1 and Oct-2 and the binding
of the T-cell-specific factor.
Figure 8. Recruitment of Oct-1, Sp1, Sp3 and PU.1 to the HS7 region in vivo.
ChIP assays were used to detect binding of transcription factors to the HS7
region in the chromosomal context of proviruses integrated in (A) ACH2
T-lymphoid cells and (B) U1 monocytic cells. DNA and protein were cross-
linked with formaldehyde for 10 min, and DNA was sheared. The cross-linked
protein–DNAcomplexeswereimmunoprecipitatedwithananti-Oct1antibody
(lane 1), an anti-Sp1 antibody (lane 2), an anti-Sp3 antibody (lane 3), an anti-
PU.1 antibody (lane 4) or with a purified rabbit IgG as negative control
(lane 5). The protein–DNA cross-links were reversed and the purified DNA
was amplified by PCR using primers amplifying the HS7 region. PCR of the
inputs (samples representing amplification from 1:100 dilution of total input
chromatin from the ChIP experiments) are shown in lane 6. The PCR control
represents the PCR amplification in the absence of DNA (lane 7).
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we substituted one adenine residue at position 4832 for
a cytosine residue and one cytosine at position 4835 for
a thymine residue (Figure 9D). The adenine residue (nt
4832)islocatedbetweentwoguanineresidueson thecod-
ing strand (nt 4830 and 4833), which were previously
demonstrated by our laboratory to be critical for complex
Dformationby methylationinterference (7). Thecytosine
residue (nt 4835) corresponds to the guanine residue pre-
viously identified on the non-coding strand by the same
technique as critical for complex D formation. The wild-
typeandthemutatedoligonucleotides(referredtoassiteD
mut) were used as probes in EMSAs with U937 nuclear
extracts. Figure 9D demonstrated that the selected 2 bp
mutation abolished formation of complex D.
TheHS7bindingsitesareinvolvedinthetranscriptional
activity of the pol gene region
Our laboratory has previously shown using chloramphenicol
acetyltransferase (CAT) transient expression plasmids that a
500bpfragmentencompassingtheHS7region(nt4481–4982)
exhibited transcription enhancing activity ( 2-fold) when it
was cloned in its natural position with respect to the HIV-1
promoter in U937 and CEM cells in the presence of Tat.
However, in the absence of Tat, the CAT values were too
low to detect any enhancing activity of the HS7 region.
In order to address the potential functional role of the HS7
region in the basal (Tat-independent) activity of the HIV-1
promoter, we used the more sensitive luciferase transient
expression system. We subcloned the 500 bp HS7 fragment
Figure 9. MutagenesisoftheHS7bindingsites.Leftpanels:Thewild-typeandmutatedoligonucleotidescorrespondingtotheHS7siteB(A),Spsite(B),siteC(C)
and site D (D) are shown. The amino acids encoded by these oligonucleotide sequences are indicated. Bases that are changed in the mutated versions of the HS7
binding sites relative to the wild-type version are underlined. Right panels: Probes (indicated at the top of each lane) were incubated with 15 mg of nuclear extracts
from U937 (A, B and D) or Raji (C) cells. The figure shows only the specific retarded bands of interest. The retarded complexes corresponding to Oct-1, Oct-2,
PU.1, Sp1, Sp3 and D are indicated by arrows.
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tothe transcriptionalunit, downstream oftheluciferasereporter
gene,therebygeneratingthepLTR-HS7wt.ThepLTRconstruct
contains the complete HIV-1 LAI 50-LTR (plus the leader
sequence up to the ATG of gag) driving the expression of
the luciferase gene. The constructs pLTR and pLTR-HS7wt
were transiently transfected into Jurkat cells (Figure 10A) or
U937 cells (Figure 10B). The reporter constructs were cotrans-
fected into the cells with pRL-TK, and used as an internal
control to measure the transfection efﬁciency. At 44 h post-
transfection,cellswerelysedandassayedforluciferaseactivity.
In Jurkat cells, transfection of plasmid pLTR-HS7wt caused a
1.58-fold increase in luciferase activity compared with that of
the control plasmid pLTR tested under the same conditions
(Figure 10A). In U937 cells, transfection of pLTR-HS7wt
caused a 1.98-fold increase in luciferase activity compared
with that of pLTR (Figure 10B). These results indicate that,
in the absence of Tat, the region associated with the intragenic
HS7 shows a weak transcriptional enhancing activity when it is
cloned in a position similar to that observed within the viral
genome (downstream and in sense orientation relative to the 50-
LTR-luc transcriptional unit).
In order to determine the relative contribution of each
factor binding sites (site B, site C, Sp site and site D) to
Figure10.FunctionalsignificanceoftheHS7bindingsites.Thetranscriptionalenhancingactivityofthewild-typeandmutatedpolgeneHS7regionswastestedafter
cloning of these regions in pLTR and transfection of the plasmids pLTR, pLTR-HS7wt, pLTR-HS7totmut pLTR-HS7mutB/Oct, pLTR-HS7mutB/PU, pLTR-
HS7mutC, pLTR-HS7mutSp, pLTR-HS7mutD and pLTR-HS7mutCmutB/Oct in Jurkat (A) or U937 (B) cells. Cells were cotransfected with 50 ng of pRL-TK in
which the HSV TK promoter is driving the Renilla luciferase gene expression. Luciferase activities (Firefly and Renilla) were measured in cell lysates 44 h after
transfection. Results are expressed as LuciferaseFirefly/LuciferaseRenilla and are presented as histograms indicating luciferase activities relative to that of the control
vector pLTR, which was assigned a value of 1. Means and standard errors of the means from 6 to 8 independent transfections performed with three different DNA
preparations are indicated.
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EMSAs (Figure 9) were introduced individually or in com-
bination in the context of the pLTR-HS7wt plasmid. The
mutated plasmids were designed pLTR-HS7totmut, pLTR-
HS7mutSp, pLTR-HS7mutD, pLTR-HS7mutB/PU, pLTR-
HS7mutB/Oct, pLTR-HS7mutC and pLTR-HS7mutCmutB/
Oct. These plasmids were assayed for luciferase activity after
transient transfection in Jurkat or U937 cells (Figure 10A or B,
respectively). Remarkably, in both cell lines, transfection of
plasmid pLTR-HS7totmut exhibited luciferase activity similar
to that obtained with the control vector pLTR, thereby dem-
onstrating that the enhancing effect observed with pLTR-
HS7wt required intact site B, site C, Sp site and site D motifs.
Moreover, in both cell lines, transfection of the plasmids con-
taining the individual mutations presented luciferase activities
similar to that obtained with the wild-type pLTR-HS7wt con-
struct. In conclusion, mutations in the HS7 binding sites in
combination abolish the transcription-enhancing activity of
the pol HS7 region, suggesting that these sites are responsible
for most of this activity. However, we could not demonstrate
the functional role played by one individual site in the HS7
enhancing activity (Figure 10A and B).
We next studied the effect of mutating the HS7 binding sites
on the response of the HIV-1 promoter to Tat. We observed
that the pol HS7 region exhibited transcriptional enhancing
activity in the presence of Tat, in agreement with our previous
results (7), and that mutations in all the HS7 binding sites in
combination abolished this activity (data not shown).
Our functional results, thus, demonstrate a positive regula-
tory role of the pol HS7 region in both Tat-independent and
Tat-dependent HIV-1 promoter-driven gene expression. These
data indicate that the loss of transcriptional enhancing activity
caused by mutations in the HS7 binding sites correlated with
the loss in factor binding to these sites. Moreover, mutation of
each HS7 binding site individually did not affect the enhanc-
ing activity of the intragenic positive regulatory region.
FunctionalanalysisoftheindividualHS7regionbinding
sites by overexpression assays
We next wanted to further characterize the functionality of
each HS7 site individually (sites for which we were able to
identify by the above experiments the bound transcription
factors) and to examine whether these transcription factors
(PU.1,Sp1,Sp3,Oct-1 andOct-2)actthroughthe HS7binding
sites. Because these transcription factors present distinct cell-
speciﬁc expression, we decided to study each site separately
by overexpression assays using for each individual factor a
cell line which does not express the factor considered. To this
end, we produced a series of artiﬁcial luciferase reporter con-
structs in which multimerized copies of each wild-type and
mutated HS7 binding sites were inserted upstream of the HSV
TK minimal promoter into the pTK construct. The resulting
constructs were cotransfected with expression vectors for the
various transcription factors(PU.1,Sp1,Sp3, Oct-1andOct-2)
and assayed for luciferase activity. The minimal TK promoter
was used instead of the HIV-1 promoter (LTR) because the
latter is known to contain binding sites for Oct, Ets and Sp
family members (29) and could have therefore complicated
the interpretation of the transfection results. In these experi-
ments, we used multimerized HS7 binding sites because
multimerization of a transcription factor binding site allows
the ampliﬁcation of its transcriptional effect.
Ectopic expression of the Oct-1 and Oct-2 transcription
factors down-regulates TK promoter activity through multi-
merized sites B and C. To determine whether the HS7 sites B
and C can act as independent regulators of transcription,
we constructed four luciferase reporter plasmids driven by
the HSV TK minimal promoter with three tandem repeats
of the wild-type and Oct-mutated site B or site C inserted
upstream of the TK promoter. These four plasmids were
referred to as p(Bwt)3TK, p(BmutOct)3TK, p(Cwt)3TK and
p(CmutOct)3TK, respectively. To examine the response of
these reporter constructs to the POU-homeodomain trans-
cription factors Oct-1 and Oct-2, murine NIH3T3 ﬁbroblats
were transiently cotransfected with each of them and increas-
ing amounts of either the Oct-1 or the Oct-2 expression vector
(Figure 11A and B, respectively) and then assayed for
luciferase activity. The murine NIH3T3 cell line was used
in these experiments because our EMSAs performed with
NIH3T3 nuclear extracts and with probes corresponding to
site B or site C revealed no binding activity corresponding
to complexes B1/C1, B2/C2, B3/C3 and even no binding at
all (data not shown).
As shown in Figure 11, the control pTK construct was
repressed by Oct-1 up to 2.22-fold (i.e. by 55%) and by
Oct-2 up to 2.12-fold (i.e. by 53%). Cotransfection of
the reporter construct p(Bwt)3TK with the Oct-1 or Oct-2
expression vectors resulted in a dose-dependent decrease in
luciferase activity by ectopically expressed Oct-1 (up to 5.00-
fold) and Oct-2 (up to 5.88-fold); thus, representing a 2.3- and
2.8-fold down-regulation when compared with the Oct-1 and
Oct-2 responses of the control pTK construct devoid of
upstream HS7 sites B. This effect required intact Oct motifs
in site B, because mutations in these motifs [p(BmutOct)3TK]
resulted in levels of Oct-1- and Oct-2-mediated repression
similar to those obtained with the control pTK (Figure 11A
and B, respectively). Similar results were obtained when
examining site C. Indeed, addition of three copies of the
HS7 site C upstream of the TK promoter [p(Cwt)3-TK]
resulted in a dose-dependent decrease in luciferase activity
by ectopically expressed Oct-1 (up to 9.09-fold) and Oct-2
(up to 5.26-fold), thus representing a 4.1-fold and 2.5-fold
down-regulation when compared with the Oct-1 and Oct-2
responses of the control pTK devoid of upstream HS7
sites C (Figure 11A and B, respectively). This effect also
required intact Oct motifs in site C [see p(CmutOct)3-TK in
Figure 11A and B].
We conclude from these experiments that ectopic Oct-1 and
Oct-2 proteins have a site B- or site C-dependent inhibitory
effect on the heterologous TK promoter containing multiple
upstream site B or site C, respectively. These results, thus,
demonstrate that the HS7 sites B and C function as negative
regulatory elements in response to ectopic Oct-1 or Oct-2
proteins in a heterologous context, suggesting that Oct-1
and Oct-2 might be negatively involved in the HS7 transcrip-
tional activity.
Ectopic expression of the PU.1 transcription factor up-
regulates TK promoter activity through multimerized site B.
In order to deﬁne the potential role of PU.1 through the PU box
of the HS7 site B, we generated a mutant derivative of the
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tandem repeats of a site B mutated in the PU box sequence.
This derivative was designated p(BmutPU.1)3TK. The con-
structs pTK, p(Bwt)3TK and p(BmutPU.1)3TK were cotrans-
fected with increasing amounts of the PU.1 expression vector
pJ6-PU.1 into PU.1-negative NIH3T3 cells (Figure 12).
Transfected cells were assayed for luciferase activity. Results
presented in Figure 12 show that the control pTK (lacking
speciﬁc PU boxes) construct was moderately transactivated
by PU.1 (up to 2.5-fold). This PU box-independent activa-
tion could be attributed to stimulation by PU.1 through
other DNA sequences present in the pTK vector. Cotransfec-
tion of the PU.1 expression vector with the reporter construct
containing three wild-type sites B [p(Bwt)3TK] resulted in a
Figure11.MultimerizedcopiesoftheHS7sitesBandCconferOct-1andOct-2down-regulationtoaheterologousminimalpromoter.NIH3T3cellsweretransiently
cotransfected with 500 ng of the pTK, p(Bwt)3TK, p(BmutOct)3TK, p(Cwt)3TK or p(CmutOct)3TK reporter construct and with increasing amounts (0, 100 and
500 ng) of either pCG-Oct-1 (A) or pCG-Oct-2 (B). To maintain the same amount of transfected DNA and to avoid squelching artifacts, the different amounts of
Oct-1/Oct-2 expression vectors cotransfected were complemented to 500 ng of DNA by using the empty pCG vector. Luciferase activities were measured in cell
lysates44haftertransfectionandwerenormalizedwithrespecttoproteinconcentrationsofthelysates.Resultsarepresentedashistogramsindicatingtheluciferase
activity of each reporter construct in the absence of ectopically expressed Oct-1 or Oct-2, which was arbitrarily assigned a value of 100% of activity. The down-
regulationoftheTKpromoterconstructsbyOct-1(A)andOct-2(B)isalsoindicated(infold).Meansoftriplicatesamplesandstandarderrorsofthemeansareshown.
An experiment representative of three independent transfections performed with at least two different DNA preparations is shown.
4300 Nucleic Acids Research, 2005, Vol. 33, No. 13dose-dependent stimulation of the luciferase activity (up to
6.8-fold); thus, representing a 2.7-fold up-regulation when
compared with the PU.1 response of the control pTK devoid
of upstream site B PU boxes. This effect required an
intact PU box in site B, because mutations in this
motif [p(BmutPU.1)3TK] resulted in levels of PU.1-
mediated transactivation similar to those obtained with the
control pTK.
We conclude from these experiments that ectopic PU.1
protein has a site B PU box-dependent stimulatory effect on
the heterologous TK promoter containing multiple upstream
sites B. These results thus establish the functional signiﬁcance
of PU.1 through the PU box present in the HS7 site B and
suggest that the transcriptional activity of the HS7 region is
positively regulated by PU.1.
Ectopic expression of the Sp1 or Sp3 transcription factors
up-regulates TK promoter activity through the HS7 Sp
binding site. To examine whether Sp1 and/or Sp3 act through
the HS7 GC-box, we produced synthetic reporter constructs in
which multimerized copies of the wild-type or mutated HS7
Sp site were inserted upstream of the TK promoter into the
pTK construct. The resulting plasmids were designated
p(Spwt)3TK or p(Spmut)3TK, respectively. To examine the
response of these reporter constructs to Sp1 and/or Sp3,
Drosophila Schneider (SL2) cells (which unlike most mam-
malian cells lack endogenous Sp factors) were transiently
cotransfected with each of them and increasing amounts of
either the Sp1 or the Sp3 expression vector (Figure 13A and
B, respectively), and then assayed for luciferase activity. The
control pTK construct was moderately transactivated by Sp1
(up to 6.5-fold) and by Sp3 (up to 7.4-fold). Addition of three
copies of the HS7 Sp site upstream of the TK promoter
resulted in a dose-dependent increase in luciferase activity
by ectopically expressed Sp1 (up to 24.1-fold) and Sp3 (up
to 65.1-fold); thus, representing a 3.7- and 8.8-fold up-regu-
lation when compared with the Sp response of the control pTK
devoid of upstream HS7 Sp sites. Mutations in the HS7 Sp
sites reversed the activating response to Sp1 and Sp3 to the
luciferase activities obtained with the control vector pTK [see
p(Spmut)3TK in Figure 13A and B]. Moreover, the coexpres-
sion of Sp1 and Sp3 together in equal amounts on each TK
reporter constructs had no more effect than either factor trans-
fected alone (data not shown).
We conclude from these experiments that ectopic Sp1 and
Sp3 proteins have a HS7 Sp site-dependent stimulatory
effect on the heterologous TK promoter containing multiple
upstream HS7 Sp sites. The ability of the concatemerized HS7
Sp site to confer transactivation by ectopically expressed Sp1
and Sp3 in a heterologous context suggests that Sp1 and Sp3
are direct contributors to the transcriptional enhancing activity
of the HS7 region.
The HS7 binding sites are critical for HIV-1 infectivity
To address the biological signiﬁcance of the HS7 binding sites
in the HIV-1 life cycle, we tested the effect of mutations
abolishing factor binding to the different sites (sites B, C,
Sp and D) on HIV-1 replication in infection experiments
with wild-type and mutant HIV-1 infectious viruses. To this
end, mutations of each site were introduced in combination
into an infectious clone of HIV-1. In vitro site-directed muta-
genesis of the DNA-binding sites was performed with a plas-
mid (pCV10) containing the ApaI (nt 2011)/EcoRI (nt 5743)
fragment of the NL4-3 HIV-1 genome and oligonucleotides
containing the mutated sites as described in Materials and
Methods. After site-directed mutagenesis and conﬁrmation
of the mutations by sequencing, the fragment (ApaI/EcoRI)
containing the mutations was subcloned back into the
corresponding restriction sites of the pCV1 plasmid. The
resulting mutant plasmid was designated pCV426 (pHIV-1*-
HS7totmut). As a control, the corresponding wild-type ApaI/
EcoRI fragment was similarly cloned into pCV1 to generate
pCV422 (pHIV-1*).
Figure 12. AbilityofmultimerizedHS7siteBmotifstoconferPU.1stimulationtoaTKminimalpromoter.NIH3T3cellsweretransientlycotransfectedwith500ng
of either pTK, or p(Bwt)3TK or p(BmutPU.1)3TK and with increasing amounts (0, 100, 250 and 500 ng) of the PU.1 expression vector, pJ6-PU.1. To maintain the
same amountof transfected DNA and to avoid squelching artifacts,the different amountsof PU.1 expression vector cotransfected were complemented to 500 ng of
DNA by using the empty pJ6 vector. Luciferase activities were measured in cell lysates 44 h after transfection and were normalized with respect to protein
concentrationsofthelysates.ResultsarepresentedashistogramsindicatingtheinductionbyPU.1(infold)withrespecttotheactivityofeachTKreporterconstruct
in the absence of PU.1, which was assigned a value of 1. Means of triplicate samples and standard errors of the means are shown. An experiment representative of
three independent transfections performed with at least two different DNA preparations is shown.
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were generated from the single-LTR-containing constructs
pCV422 and pCV426 by BamHI digestion and self-ligation.
To obtain stocks of infectious viruses, these proviruses were
transfected into Jurkat cells. Transfected cells were coculti-
vated with SupT1 cells for 1 day after transfection. Progeny
virus production in coculture supernatants was then monitored
by measuring the level of p24 gag antigen over a 15 day
period. Cell-free supernatants were harvested at the peak of
viral production to generate virus stocks for subsequent infec-
tivity studies. To assess the possibility of reversion to a wild-
type phenotype as an explanation for the growth of the mutant
virus, HIV-1 genomic RNA from HIV-1*-HS7totmut virus
stock was puriﬁed and analyzed by RT–PCR with a primer
pair that ampliﬁed a 640 bp intragenic portion of the genome
(nt 4342–4982) encompassing the mutated HS7 binding sites.
PCR fragments were subcloned, and three individual clones
were resequenced. This analysis conﬁrmed the presence of the
original mutations in the HS7 region (data not shown).
To study the effect of the HS7 mutations on HIV-1 growth
kinetics, we infected either human CD4
+ T-lymphoid Jurkat or
human promonocytic U937 cells with the wild-type (HIV-1*)
and mutant (HIV-1*-HS7totmut) viral stocks. We performed
at least three replication assays with the Jurkat T-cell line and
with the U937 monocytic cell line by measuring p24 produc-
tion over time. Figure 14 shows a representative replication
curve for each cell line, which revealed differences in replica-
tion rate between the wild-type and the HS7 mutant viruses.
Infection of Jurkat cells with the wild-type virus resulted in
rapid and vigorous viral production, with p24 concentration
reaching a peak on days 20–25 post-infection, followed by
a rapid decrease reﬂecting a rapid reduction in viable cell
numbers (Figure 14A). Mutant virus HIV-1*-HS7totmut repli-
cated with a replication kinetics that was similar to that of the
Figure 13. AbilityofmultimerizedHS7SpmotifstoconferSp1andSp3stimulationtoaTKminimalpromoter.SL2cellsweretransientlycotransfectedwith700ng
ofeitherpTK,orp(Spwt)3TKorp(Spmut)3TKandwithincreasingamounts(0,5,10,25,50,100and250ng)ofeithertheSp1ortheSp3expressionvector,pPac-Sp1
or pPac-Sp3 [(A)o r( B), respectively]. To maintain the same amount of transfected DNA and to avoid squelching artifacts, the different amounts of Sp expression
vectorcotransfectedwerecomplementedto250ngofDNAbyusingtheemptypPacvector.Luciferaseactivitiesweremeasuredincelllysates44haftertransfection
and were normalized with respect to protein concentrations of the lysates. Results are presented as histograms indicating the induction by Sp1 or Sp3 (in fold) with
respect to the activity of each TK reporter construct in the absence of Sp, which was assigned a value of 1. Means of triplicate samples and standard errors of the
means are shown. An experiment representative of three independent transfections performed with at least two different DNA preparations is shown.
4302 Nucleic Acids Research, 2005, Vol. 33, No. 13Figure 14. Mutations in the HS7 binding sites cause a reduced efficiency of HIV-1 replication. Jurkat (A–C) or U937 (D–F) cells were infected with equivalent
amounts of p24 concentration of wild-type (HIV-1 or HIV-1*), totally mutated (HIV-1-HS7totmut or HIV-1*-HS7totmut) or individually mutated (HIV-1-
HS7mutB/PU, HIV-1-HS7mutB/Oct, HIV-1-HS7mutC, HIV-1-HS7mutCmutB/Oct, HIV-1-HS7mutSp and HIV-1-HS7mutD) viral infectious stocks as described
in Materials and Methods. Results show viral production, which was estimated by measuring p24 antigen concentration in culture supernatants at different times
followinginfection.Theexperimentshownisrepresentativeofatleastnineindependentinfectionexperimentsandthevariationforagivenmutantbetweendifferent
experiments was <15% in most cases.
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the mutant HIV-1*-HS7totmut virus produced lower p24
release (about two times less than the amount released from
cultures infected with the wild-type HIV-1* at the peak of
infection), demonstrating reduced growth properties. Similar
resultswere obtainedwhenthe growthproperties ofthe mutant
HIV-1*-HS7totmut were assayed on the human promonocytic
U937 cell line (Figure 14B). These data are consistent with
those obtained after transient expression assays (Figure 10).
In order to further evaluate the effect of the HS7 mutations
on HIV-1 replicative properties, we next introduced indivi-
dually the mutations into the two-LTRs-containing infectious
HIV-1 molecular clone pNL4-3. The wild-type and totally
mutated proviruses were also generated in this context. The
resulting proviruses were designated as pHIV-1, pHIV-1-
HS7totmut, pHIV-1-HS7mutB/Oct, pHIV-1-HS7mutB/PU,
pHIV-1-HS7mutC, pHIV-1-HS7mutSp, pHIV-1-HS7mutD
and pHIV-1-HS7mutCmutB/Oct. Stocks of infectious viruses
wild-type, totally mutated or containing the individual muta-
tions were generated by transfection of 293T cells, were tested
for the presence of the original muations by RT–PCR and
sequencing analyses, and were used in infection studies of
Jurkat and U937 cells (see Materials and Methods). HIV-1
replication was monitored by measuring the production of
p24 in the cell supernatants over a  15 day period. On the
basis of their growth characteristics, the ﬁve individual and the
double HS7 mutant viruses were classiﬁed into two replicative
phenotypes.
In Jurkat cells, (i) mutant viruses HIV-1-HS7mutB/Oct
and HIV-1-HS7mutC replicated efﬁciently with replication
kinetics similar to that of the wild-type control virus
HIV-1, but with levels of viral production slightly lower
than that of the control virus, indicating that the individual
mutations of the octamer sequence either in site B or in site C
slightly affected HIV-1 replication but not as strongly as the
combination of all the HS7 mutations (compare with HIV-
1-HS7totmut) (Figure 14B and C); and (ii) mutant viruses
HIV-1-HS7mutB/PU, HIV-1-HS7mutCmutB/Oct, HIV-1-
HS7mutSp and HIV-1-HS7mutD also replicated with a
replication kinetics that was similar to that of the wild-type
control virus. However, infection with these mutant viruses
produced p24 release as low as the totally mutated virus,
demonstrating reduced growth properties similar to those
observed with HIV-1-HS7totmut (Figure 14C).
In U937 cells, (i) mutant viruses HIV-1-HS7mutB/Oct,
HIV-1-HS7mutC, HIV-1-HS7mutCmutB/Oct and HIV-1-
HS7mutD replicated efﬁciently with replication kinetics and
levels of viral production that were similar to those of the
wild-type control virus HIV-1, indicating that the individual
mutations of the octamer sequence either in site B or in site C,
the individual mutation of site D and the double mutation of
the octamer sequences in both site B and site C did not affect
HIV-1replication(Figure14E);and(ii)mutantvirusesHIV-1-
HS7mutB/PU and HIV-1-HS7mutSp also replicated with a
replication kinetics that was similar to that of the wild-type
HIV-1. However, infection with these mutant viruses pro-
duced lower p24 release than the wild-type HIV-1, demon-
strating reduced growth properties similar to those observed
with HIV-1-HS7totmut (Figure 14F).
Further infection of target cells in a second round with
supernatants collected 15 days after the ﬁrst infection
indicated that all the HS7 mutant viruses were not impaired
in terms of infectivity (data not shown).
Thus, the integrity of the HS7 DNA-binding sites located
5 kb downstream of the HIV-1 transcription start site is impor-
tant for HIV-1 replication in human CD4
+ cell lines, indicating
a positive regulatory function for this region. Our ﬁndings
strongly suggest a crucial role of the HS7 Sp and PU.1
sites on HIV-1 replication.
Mutations in the HS7 binding sites do not affect the
integrity of the viral particles
Although mutations in the HS7 region are not expected to
impair HIV-1 RNA packaging, we performed RNase protec-
tion assays to quantify viral RNA from equal amounts of viral
particles from the wild-type and each HS7 mutant virus
stocks (Figure 15A). This experiment showed that the wild-
type and mutant viruses contained the same amount of pack-
aged genomicRNA (Figure 15A). Moreover, we also analyzed
the amount of HIV-1-speciﬁc proteins in the wild-type and
each HS7 mutant virus stock (Figure 15B). To this end, lysates
from equal amounts of p24 from the wild-type and mutant
virus stocks were prepared, and western blot analyses were
performed with puriﬁed human anti-HIV-1 IgG as a source of
antibody. Similar levels of the HIV-1 proteins (including the
integrase which is partially encoded by the HS7 region) were
detected in all lysates (Figure 15B).
These results demonstrate that the reduced replication phe-
notypes we observed with the HIV-1 HS7 mutant viruses are
due neither to a defect in RNA packaging nor to a defect in the
protein content of viral particles. Thus, mutant and wild-type
HIV-1 particles from the viral stocks used in the infection
studies are structurally undistinguishable at both the genomic
RNA and the protein levels, suggesting an effect of the muta-
tions in the HS7 cis-acting elements at the level of HIV-1
transcription.
DISCUSSION
We have previously identiﬁed and physically characterized
a new positive transcriptional regulatory element associated
with a DNase I-hypersensitive site (HS7) present in the pol
gene of HIV-1 (7). A fragment encompassing this hyper-
sensitive site positively regulates transcription from the
HIV-1 50-LTR in transient transfection experiments. Several
recognition sites for nuclear proteins (sites B, C, D and a
GC-box) have been identiﬁed by in vitro binding studies
(7). In this study, we have further physically characterized
each of these four binding sites located in the HS7 region
and have shown that the transcription factors Oct-1, Oct-2,
PU.1, Sp1 and Sp3 interact in vitro with this region. Other
in vitro binding studies have also shown that Tat expression
does not affect the binding of the nuclear factors to the HS7
binding sites. Furthermore, ChIP assays have revealed that
Sp1, Sp3, Oct-1 and PU.1 are recruited in vivo to the HS7
intragenic region of HIV-1 proviruses integrated in several
infected cell lines (Figure 16). For each of the four sites
(sites B, Sp, C and D), we have identiﬁed point mutations
abolishing binding of the nuclear factors to their cognate
DNA sites without altering the underlying amino acid
sequence of the integrase. By transient transfection assays,
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binding sites in the transcriptional enhancing activity of the
pol gene region. We have next examined the functional tran-
scriptional role of each site separately in a heterologous con-
text. Our results with multimerized wild-type and mutated
HS7 binding sites in isolation (i.e. in the absence of the
other DNA-binding sites) have demonstrated that the PU.1,
Sp1 and Sp3 transcription factors, on one hand, and the Oct-1
and Oct-2 transcription factors, on the other hand, up- and
down-regulate, respectively, the transcriptional activity of
the minimal TK promoter. Finally, we have addressed the
biological signiﬁcance of the HS7 binding sites in the HIV-
1 replication cycle by mutating these sites individually or in
combination in the context of infectious clones of HIV-1.
These mutationsdonot affect the integrity ofthe viral particles
both at the genomic RNA and the protein levels. Our infection
studies have demonstrated that the HS7 sites located 5 kb
downstream of the HIV-1 transcription start site are important
for HIV-1 replication in human CD4
+ cell lines, indicating a
positive regulatory function for pol intragenic region.
Figure 15. Mutations in the HS7 binding sites do not affect viral particle formation. (A) Equivalent amounts of viral particles (assessed by p24 ELISA assay) from
the wild-type and each HS7 mutant virus stocks were pelleted by ultracentrifugation. After lysis of viral particles, HIV-1 RNA was detected by RNase protection
analysiswithanantisenseriboprobewhichprotectstwobands(200and83nt)correspondingtotheHIV-130-and50-LTR,respectively.TheundigestedHIVprobeis
shownforreference.LaneMarker(M)containspSK-/ApaIImarkers,whosesizes(innt)areindicatedontheleft-handside.IntensitiesofRNAbandswerequantified
byradioimaging(InstantImager).(B)Equivalentamountsofviralparticles(assessedbyp24ELISAassay)fromthewild-typeandeachHS7mutantvirusstockswere
pelleted by ultracentrifugation. The ultracentrifuged viral stocks were lysed in Laemmli buffer, analyzed by western blotting with anti-HIV-1 immunoglobulin,
and detected by enhanced chemiluminescence with a horseradish peroxidase-conjugated goat anti-human IgG. The bands corresponding to the HIV-1 reverse
transcriptase, integrase, p24 protein and protease are indicated. MW, molecular mass (indicated in kDa).
Figure 16. Putative schematic representation of the nuclear factors binding to their respectiveDNA sites in the intragenic HS7 region of HIV-1.This assignmenti s
based on in vitro binding studies. Moreover, the transcription factors Oct-1, Sp1, Sp3 and PU.1 have also been demonstrated by ChIP assays to be recruited to the
HS7regioninvivointhechromosomalcontextofintegratedproviruses.TheDNA-bindingsitesarerepresentedasclosedrectangles.Theubiquitousnuclearfactors
arerepresentedasgray-shadedovals,whereasfactorsspecifictoagivencelllineappearasopencircles.Ourexperimentsdonotestablishwhetherthenuclearfactors
indeed bind together, successively or alternatively to their cognate DNA sequences.
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Octamer binding sites. By in vitro binding studies, we have
demonstrated that the HS7 sites B and C speciﬁcally bind the
octamer proteins Oct-1 and Oct-2. In addition, we have shown
by ChIP assays the binding of the Oct-1 protein to the HS7
region in vivo both in the HIV-1 latently infected T-lymphoid
cell line ACH2 and in the monocytic cell line U1. Octamer
binding proteins belong to the POU homeodomain transcrip-
tion factor family (30). Two of the best characterized octamer
binding proteins are Oct-1 and Oct-2. Whereas the Oct-1
protein is ubiquitously expressed, Oct-2 is expressed pre-
dominantly in the B-cell lineage (31–35). However, Oct-2
expression can be induced by antigenic stimulation of
T-cells (36), suggesting that the Oct-2 protein may play a
role in gene expression during T-cell activation. Oct-1 is a
broadly expressed and versatile transcription factor perform-
ing many divergent roles in cellular and viral transcriptional
regulation and acting both as a repressor and as an activator
of transcription [reviewed in (37)].
Using transient transfection assays, we have shown that
ectopically expressed Oct-1 and Oct-2 repress the transcrip-
tional activity of the minimal TK promoter through the HS7
sites B and C. However, our infection experiments using
viruses mutated in the octamer sequences of site B and/or
site C are not consistent with a repressive effect mediated by
these sites. Indeed, in U937 cells, the individual mutations of
the octamer sequences either in site B or in site C as well as the
double mutation of the octamer sequences in both site B and
site C do not affect HIV-1 replication. In Jurkat cells, the
individual Oct mutations slightly reduce the levels of viral
production relative to those observed with the wild-type
virus, whereas the mutant virus containing the double Oct
mutation demonstrates more severely reduced growth proper-
ties similar to those observed with the totally mutated virus
HIV-1-HS7totmut. Different hypotheses can be drawn to
explain these discrepancies between our ex vivo transfection
and in vivo infection results. First, assays using synthetic
reporter constructs with multimerized binding sites may not
be representative of the regulation, which takes place in the
complete regulatory HS7 region and involves interactions
between proteins binding to adjacent elements. A second
possible explanation is that, in our ex vivo studies, the vectors
containing the mutations in the octamer sequences are trans-
fected in cells which do not express Oct-1/Oct-2, the nuclear
T-lymphoid factors B3/C3 or the PU.1 protein. In contrast, the
Jurkat or U937 cells used in the infection studies contain Oct-1
and B3/C3 or Oct-1 and PU.1, respectively, thereby represent-
ing a more complex biological system. Third, transient trans-
fection experiments may not reﬂect the regulation found
in vivo with the intact provirus since transiently transfected
DNA is not assembled into physiological chromatin. Similar
discrepancies between transient transfection studies and
in vivo functional studies have been previously reported for
HIV by different groups including our laboratory (20,38–40).
More speciﬁcally, regarding the HS7 Oct binding sites, the
functional effect of the individual mutations in site B/Oct or
site C/Oct could compensate each other; and the functional
effect of the combined mutation site B/Oct+site C/Oct could
be compensated by other factors binding to the HS7 region and
still unidentiﬁed. In Jurkat cells, mutation of the octamer
sequence of site B or site C does abolish not only the binding
of Oct-1, but also the binding of the T-cell-speciﬁc factor B3/
C3, which makes impossible to functionally distinguish in
infection studies between the role of Oct-1 and the role of
the T-cell factor. In U937 cells, mutation in the octamer
sequence of site B abolishes the binding of Oct-1 but not
the binding of PU.1. However, we can not exclude the pos-
sibility that the mutation of the Oct sequence might affect the
binding of PU.1 in vivo. Indeed, our in vitro binding studies
suggest that the binding of these two proteins to site B is
mutually exclusive.
We have demonstrated that the PU.1 protein, which binds to
site B, activates the transcriptional activity of the TK promoter
through the HS7 site B. Therefore, in monocytes/macophages,
the competition between Oct-1 and PU.1 both expressed in
these cells for binding to their respective overlapping cognate
sequences in the HS7 site B could determine the global con-
tribution of site B to the transcriptional activity of the pol
intragenic region. In T-cells, in which PU.1 is not expressed,
such a competition between Oct-1 and the T-cell-speciﬁc fac-
tor (B3/C3) could similarly takesplace inbothsiteBandsiteC
and could therefore determine the contribution of these two
sites to the HS7 transcriptional activity. Previous publications
have reported links between the Oct-1 protein and the HIV-1
transcriptional regulation. Indeed, Liu and Latchman (41)
have previously identiﬁed four potential Oct binding sites
in the HIV-1 LTR. In this latter study, Oct-1 has been
shown to repress HIV-1 LTR promoter activity and its trans-
activation by Tat (41). A more recent study contrasts with the
latter one and demonstrates that Oct-1 and Oct-2 fail to bind
the HIV-1 LTR, and that overexpression of Oct proteins has no
effect on HIV-1 transcription or replication in primary human
CD4
+ T-cells (42). Interestingly, the role of Oct-1 in HIV-1
transcription has also been indirectly highlighted by Bahr and
co-workers. They have demonstrated that murabutide, which
is a clinically acceptable immunomodulator presenting the
capacity to decrease HIV-1 transcription (43,44), presents
the ability to induce Oct-1 expression and DNA-binding activ-
ity in HIV-1 infected macrophages (45). These results suggest
that the murabutide-induced suppression of HIV-1 trans-
cription could be mediated, at least in part, by its capacity
to increase Oct-1 expression (45). In the present study, we
have demonstrated that the HIV-1 HS7 sites B and C bind
Oct-1 and Oct-2 and confer transrepression by ectopically
expressed Oct-1 and Oct-2 in reporter gene assays. Therefore,
these results suggest that the murabutide-induced repression
of HIV-1 transcription reported by Darcissac et al. (43) could
be correlated to its capacity to increase the expression of Oct-1
and its subsequent binding to the HS7 sites B and C. Thus,
further exploration of the role of Oct transcription factors
in the activity of the HIV-1 LTR are warranted. Moreover,
it would be interesting to study the relative contribution of the
debated LTR Oct sites and of the HS7 Oct sites identiﬁed in
this report to HIV-1 transcriptional regulation.
PUboxbindingsite.Wehavedemonstrated invitro andinvivo
that the HS7 site B is speciﬁcally bound by the PU.1 protein.
PU.1 is an ETS family transcription factor that is highly
expressed in B-lymphocytes, myeloid cells and immature
erythrocytes (46,47). PU.1 binding motifs are found in a
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ciﬁc transcription elements (48). Using transient transfection
assays, we have demonstrated that ectopic PU.1 protein has a
site B PU box-dependent stimulatory effect on the hetero-
logous TK promoter containing multiple upstream sites B.
Consistently, we have demonstrated by infection studies in
U937 cells that virus mutated in the HS7 site B PU box pre-
sentsreducedgrowthkineticswhencomparedwithawild-type
virus, thereby supporting the notion that PU.1 positively
regulates the transcriptional activity of the HS7 region. The
individual mutation of the site B PU box also reduces the
efﬁciency of HIV-1 replication in the PU.1-negative Jurkat
T cell line. It is worth noting that, although our EMSA experi-
ments did not allow us to demonstrate in T-cells the binding
of proteins to the PU box, we cannot exclude the possibility
that this motif might be occupied by another protein in vivo.
Another possible explanation is that some bases in the PU box
could be important for the recruitment of co-factors for the
Oct-1 protein whose binding sequence in site B is located just
next to the PU box motif.
DNA regulatory regions in eukaryotic genomes frequently
adopt a nuclease-hypersensitive conﬁguration (49). This
hypersensitivity is thought to result from the disruption of
the packaging of DNA into nucleosomes by DNA-bound regu-
latory proteins. The absence of a hypersensitive site in the
pol gene of HIV-1 integrated in two chronically infected
T-cell lines (ACH2 and 8E5) could be due to differences in
nucleotide sequence among HIV-1 isolates or to the presence
of different regulatory factors in different cell types (lymphoid
versus monocyte/macrophage cells). It is also possible that
the pol region is nucleosome free in ACH2 and 8E5 cells
but is occupied by bound factors in such a way as to adopt
a conﬁguration resistant to nuclease digestion. The ChIP
assays reported here provide additional information on this
issue and support the latter possibility. Indeed, these assays
demonstrate the recruitment of Oct-1, Sp1 and Sp3 to the HS7
region in vivo both in T-lymphoid (ACH2) and in monocytic
(U1) HIV-1-infected cells. Moreover, we have shown by ChIP
assays that, in addition to Oct-1, Sp1 and Sp3, PU.1 also
occupies the HS7 region in U1 cells and could therefore be
involved in the nuclease hypersensitivity of the intragenic
region in these cells. Indeed, studies on the B-cell-speciﬁc
m and k30 enhancers have shown that PU.1 is involved in
chromatin remodeling events by functioning in some contexts
as an accessibility factor (i.e. a protein capable of binding its
site in the repressive context of chromatin, thereby increasing
accessibility of the region) (50–52). Therefore, the presence
in the pol gene of HIV-1 of a regulatory region containing a
binding site for the macrophage and B-cell-speciﬁc factor
PU.1 and associated with a monocyte-speciﬁc nuclease hyper-
sensitive site suggests that PU.1 could act through the HS7
site B as an accessibility factor triggering the open chromatin
conﬁguration in the pol region. Further work including muta-
tion and in vitro chromatin reconstruction studies is needed
to investigate this hypothesis.
Although previous studies have demonstrated that the
HIV-1 macrophage tropism is primarily determined at the
level of the entry, several reports have highlighted additional
determinants of macrophage tropism present at the level of
transcription. Indeed, two motifs located in the HIV-1 LTR
bind members of the C/EBP family of transcription factors
and are required for virus replication in macrophages, but not
T-cells (53–55). The tropism of other viruses for their target
cells is determined in part at the transcriptional level. In mur-
ine leukemia viruses, a switch in tropism to T-cells was found
to be caused by alterations in the U3 region of the LTR (56).
The enhancer element of lymphotropic papovavirus, which
contains a PU box required for its activity, contributes to
the restricted tropism of the virus for primate B lymphocytes
(57). The LTR enhancer of all known virulent strains of
the equine infectious anemia virus (EIAV) contains three
Ets binding motifs that interact with the transcription factor
PU.1 and that are necessary for viral transcription in primary
macrophages (58–60). Finally, our laboratory has identiﬁed a
functional PU box in the bovine leukemia virus LTR (61).
Sp binding site. We have demonstrated by in vitro binding
experiments that the HS7 GC-box is speciﬁcally bound by the
Sp1 and Sp3 proteins. The recruitment of both proteins to the
pol region was also demonstrated in vivo in the ACH2 and U1
cell lines. Using transient transfection assays, we have shown
that ectopically expressed Sp1 and Sp3 have a positive effect
on a luciferase reporter plasmid containing three copies of the
HS7 Spsiteclonedupstream ofthe heterologous promoterTK.
In vivo, we have shown that the mutant virus containing the
mutation in the HS7 Sp site demonstrates a reduced replicative
phenotype similar to that observed with the totally mutated
virus HIV-1-HS7totmut, thereby indicating a positive regula-
tory function of the Sp site.
The Sp family of transcription factors comprises eight
members (Sp1–Sp8) [reviewed in (62,63)]. The most studied
members of the Sp family, Sp1 and Sp3, are ubiquitously
expressed but also fulﬁl distinct functions, as has been indi-
cated by gene ablation studies (64,65). Sp1 is often described
as a general activator of transcription, whereas Sp3 can act
as an activator or as a repressor of Sp1-mediated activation,
depending on the sequence context, the number of Sp binding
sites and the availability of speciﬁc coactivators, corepressors
or other transcription factors. However, the interplay between
Sp1 and Sp3 in the regulation of speciﬁc promoters and the
way the cells used the combination of these two related tran-
scriptionfactorsto regulate gene expression isnot clear. In this
study, we have demonstrated that both Sp1 and Sp3 proteins
have a HS7 Sp site-dependent stimulatory effect in the context
of a heterologous promoter. In some systems including the
HIV-1 LTR (13,66), Sp3 has been shown to cause repression
ofSp1-mediatedtranscriptionalactivation.However,wecould
not observe such an inhibitory activity for TK transcription
as shown in Drosophila SL2 cells transfected with both the
Sp1 and Sp3 expression vectors (data not shown). Such a lack
of repression of Sp1-mediated transcriptional activation
by Sp3 has been previously reported for the IL-10 promoter
regulation (67).
The Sp1 protein has been shown to mediate the formation of
DNA loops between Sp1 proteins bound at two different sites
on a DNA molecule (68–70). This DNA bending induced by
Sp1 may play a direct role in the activation of transcription
by bringing together factors bound at non-adjacent sites or
facilitating binding of factors involved in the formation of
an initiation complex. The presence of three tandemly
arranged Spl sites in the HIV-1 50-LTR and of one Spl site
in the pol nuclease-hypersensitive site suggests a putative
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bring in close proximity other factors bound to the 50-LTR and
to the pol regulatory element, and this arrangement could play
a role in transcriptional regulation of the HIV-1 promoter.
Similarly, Sp protein interactions could take place between
the pol Sp site and the two juxtaposed Sp1 binding sites pre-
viously identiﬁed by our laboratory in the leader region posi-
tive transcriptional regulatory element (20).
Site D. We have previously published that site D speciﬁcally
binds an ubiquitously expressed factor (7). In this report,
despite many in silico and experimental attempts, we were
unable to identify the factor(s) binding to site D. However, we
have demonstrated that the binding of the ubiquitously
expressed protein(s) to site D is Zn
2+-dependent. This obser-
vation suggests that this (these) protein(s) could contain zinc
ﬁnger domain(s). Our infection studies have demonstrated
that a virus mutated in the HS7 site D replicates as efﬁciently
as the wild-type control virus in the monocytic cell line U937.
In contrast, in Jurkat T cells, the same mutant virus demon-
strates reduced growth properties similar to those of the
totally mutated virus HIV-1-HS7totmut, thereby demonstrat-
ing in vivo the biological signiﬁcance of this site in the HIV-1
life cycle.
Since complex D is ubiquitous, this difference in terms of
replication between the two cell types cannot be attributed
to the presence or the absence of the D factor(s) in one cell
line. However, numerous explanations have been proposed to
explain how a ubiquitously expressed factor can participate
in lineage-speciﬁc gene regulation. For instance, limited
access of the ubiquitous factor to its cognate DNA sequence
or post-translational modiﬁcations of the factors, such as phos-
phorylation, acetylation and glycosylation, have been reported
as important for tissue-speciﬁc regulation. Moreover, protein–
protein interactions between ubiquitous and cell-speciﬁc tran-
scription factors could also contribute to cell type-speciﬁc
transcriptional control.
We have thus demonstrated an important physiological role
of the pol region in HIV-1 replication. The growth properties
of a virus containing combined mutations abolishing nuclear
factor binding to all the HS7 sites (site B, Sp site, site C and
site D) are reduced when compared with those of a wild-type
HIV-1. This reduced replicative phenotype is observed both in
the Jurkat T-cell line and in the U937 monocyte/macrophage
cell line and is indicative of a positive regulatory function for
the pol intragenic region. No defect in RNA-packaging and no
defect in the protein content of viral particles could be mea-
sured for any of the mutant viruses as determined by quanti-
ﬁcation of their HIV genomic RNA (by RNAse protection
assay) and as determined by western blotting analysis, respec-
tively. Therefore, our results suggest that the reduced replica-
tive phenotypes of the HS7 mutant viruses are due to a
decreased level of transcription as the result of point mutations
in the HS7 region and that the cis-acting DNA elements we
identiﬁed here, within this region, are required for optimal
LTR transcriptional activity. Consistent with this hypothesis,
our ﬁndings indicate that the loss of transcriptional enhancing
activity of the pol regulatory region and the reduced replica-
tive phenotype of HIV-1 caused by mutations in the HS7
binding sites correlate with the loss in factor binding to
these sites.
Why does HIV-1 need two enhancers? During the course of
infection, HIV-1 has to replicate in different cell types which
can present various activation states. The presence of different
transcriptional regulatory elements in the viral genome may
suggest a viral strategy to be productive across several cellular
environments with large differences in the pool of transcrip-
tion factors. Indeed, it is estimated that more than 2000 tran-
scription factors are encoded by the human genome (71,72).
These factors are not equally expressed in all cell types, and
many can be activated at speciﬁc stages of the cell develop-
mental programme. The transcriptional environment of HIV-1
is therefore multidimensional, as the pool of transcription
factors varies both temporally and spatially. Therefore, the
redundancy and overlap in the transcription factor binding
sites found in the HIV-1 genome could represent a solution
for the virus to ensure its replication in several cellular envi-
ronments. Our results demonstrate that the HS7 region is com-
posed of multiple factor binding sites; some of these factors
are ubiquitously expressed (Oct-1, Sp1/Sp3 and complex D),
whereas others are cell-speciﬁc factors (PU.1, T-cell
complexes B3/C3), supporting the notion that the HS7 tran-
scriptional activity is determined by a combinatorial control:
the combined action of tissue-restricted and ubiquitously
expressed proteins. The HS7 regulatory region described in
this report could either bring additional cellular speciﬁcity, or
increase the strength of the promoter/enhancer unit located in
the HIV-1 LTR, or allow viral responses toabroadervarietyof
exogenous stimuli. Other viruses have been shown to possess
intragenic regulatory regions. For example, the presence of
two enhancer regions contributing to transcriptional regula-
tion by adding a cellular speciﬁcity has been previously
reported for the human hepatitis B virus and the closely related
woodchuck hepatitis virus (73,74).
In conclusion, the pol positive cis-regulatory element
located in the transcribed region of the HIV-1 genome brings
an additional factor in an already complex network of
regulators affecting the level of HIV-1 replication. Such a
complexity could allow a ﬁner-tuned regulation than a simple
‘On/Off’ switching mechanism; this ﬁne-tuning might ﬁnd
its purpose when HIV-1 transcription needs to be moderately
and/or transiently modiﬁed.
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